<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Pharmacological treatment for Buerger's disease - Cacione, DG - 2020 | Cochrane Library</title> <meta content="Pharmacological treatment for Buerger's disease - Cacione, DG - 2020 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011033.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Pharmacological treatment for Buerger's disease - Cacione, DG - 2020 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011033.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD011033.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Pharmacological treatment for Buerger's disease" name="citation_title"/> <meta content="Daniel G Cacione" name="citation_author"/> <meta content="UNIFESP – Escola Paulista de Medicina" name="citation_author_institution"/> <meta content="dancac@gmail.com" name="citation_author_email"/> <meta content="Cristiane R Macedo" name="citation_author"/> <meta content="Centro de Estudos de Saúde Baseada em Evidências e Avaliação Tecnológica em Saúde" name="citation_author_institution"/> <meta content="Frederico do Carmo Novaes" name="citation_author"/> <meta content="UNIFESP – Escola Paulista de Medicina" name="citation_author_institution"/> <meta content="Jose CC Baptista-Silva" name="citation_author"/> <meta content="Universidade Federal de São Paulo" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="5" name="citation_issue"/> <meta content="10.1002/14651858.CD011033.pub4" name="citation_doi"/> <meta content="2020" name="citation_date"/> <meta content="2020/05/04" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011033.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011033.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011033.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Alprostadil [therapeutic use]; Amputation, Surgical [statistics &amp; numerical data]; Aspirin [therapeutic use]; Epoprostenol [analogs &amp; derivatives, therapeutic use]; Folic Acid [therapeutic use]; Hematinics [therapeutic use]; Iloprost [therapeutic use]; Pain [drug therapy]; Placebos [therapeutic use]; Platelet Aggregation Inhibitors [*therapeutic use]; Prostaglandins [therapeutic use]; Randomized Controlled Trials as Topic; Thromboangiitis Obliterans [*drug therapy, surgery]; Ulcer [drug therapy]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011033.pub4&amp;doi=10.1002/14651858.CD011033.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011033.pub4&amp;doi=10.1002/14651858.CD011033.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011033.pub4&amp;doi=10.1002/14651858.CD011033.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011033.pub4&amp;doi=10.1002/14651858.CD011033.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011033.pub4&amp;doi=10.1002/14651858.CD011033.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011033.pub4&amp;doi=10.1002/14651858.CD011033.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011033.pub4&amp;doi=10.1002/14651858.CD011033.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011033.pub4&amp;doi=10.1002/14651858.CD011033.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011033.pub4&amp;doi=10.1002/14651858.CD011033.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011033.pub4&amp;doi=10.1002/14651858.CD011033.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011033.pub4&amp;doi=10.1002/14651858.CD011033.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011033.pub4&amp;doi=10.1002/14651858.CD011033.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011033.pub4&amp;doi=10.1002/14651858.CD011033.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011033.pub4&amp;doi=10.1002/14651858.CD011033.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011033.pub4&amp;doi=10.1002/14651858.CD011033.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011033.pub4&amp;doi=10.1002/14651858.CD011033.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011033.pub4&amp;doi=10.1002/14651858.CD011033.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011033.pub4&amp;doi=10.1002/14651858.CD011033.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011033.pub4&amp;doi=10.1002/14651858.CD011033.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011033.pub4&amp;doi=10.1002/14651858.CD011033.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011033.pub4&amp;doi=10.1002/14651858.CD011033.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011033.pub4&amp;doi=10.1002/14651858.CD011033.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011033.pub4&amp;doi=10.1002/14651858.CD011033.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="7a2tKMcJ";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD011033\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD011033\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011033\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011033\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ru","ms","fa","pl","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD011033.pub4",title:"Pharmacological treatment for Buerger\u0027s disease",firstPublishedDate:"May 4, 2020 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Vascular Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=7a2tKMcJ&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011033.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011033.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD011033.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD011033.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011033.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD011033.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD011033.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD011033.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD011033.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD011033.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4771 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD011033.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011033.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011033.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011033.pub4/full#CD011033-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011033.pub4/full#CD011033-sec-0088"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011033.pub4/full#CD011033-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011033.pub4/full#CD011033-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011033.pub4/full#CD011033-sec-0015"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011033.pub4/full#CD011033-sec-0016"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011033.pub4/full#CD011033-sec-0043"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011033.pub4/full#CD011033-sec-0078"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011033.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011033.pub4/appendices#CD011033-sec-0093"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011033.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011033.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/table_n/CD011033StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/table_n/CD011033StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011033.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011033.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011033.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011033.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011033.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD011033.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Pharmacological treatment for Buerger's disease</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011033.pub4/information#CD011033-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Daniel G Cacione</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011033.pub4/information#CD011033-cr-0005">Cristiane R Macedo</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011033.pub4/information#CD011033-cr-0006">Frederico do Carmo Novaes</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011033.pub4/information#CD011033-cr-0007">Jose CC Baptista-Silva</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/information/en#CD011033-sec-0104">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 04 May 2020 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD011033.pub4">https://doi.org/10.1002/14651858.CD011033.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD011033-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011033-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011033-abs-0013">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011033-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011033-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011033-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD011033-abs-0001" lang="en"> <section id="CD011033-sec-0001"> <h3 class="title" id="CD011033-sec-0001">Background</h3> <p>Buerger's disease (thromboangiitis obliterans) is a non‐atherosclerotic, segmental inflammatory pathology that most commonly affects the small and medium sized arteries, veins, and nerves in the upper and lower extremities. The aetiology is unknown, but involves hereditary susceptibility, tobacco exposure, immune and coagulation responses. In many cases, there is no possibility of revascularisation to improve the condition. Pharmacological treatment is an option for patients with severe complications, such as ischaemic ulcers or rest pain.This is an update of the review first published in 2016. </p> </section> <section id="CD011033-sec-0002"> <h3 class="title" id="CD011033-sec-0002">Objectives</h3> <p>To assess the effectiveness of any pharmacological agent (intravenous or oral) compared with placebo or any other pharmacological agent in patients with Buerger's disease. </p> </section> <section id="CD011033-sec-0003"> <h3 class="title" id="CD011033-sec-0003">Search methods</h3> <p>The Cochrane Vascular Information Specialist searched the Cochrane Vascular Specialised Register, Cochrane Central Register of Controlled Trials, MEDLINE, Embase, CINAHL, AMED, the World Health Organization International Clinical Trials Registry Platform and ClinicalTrials.gov trials register to 15 October 2019. The review authors searched LILACS, ISRCTN, Australian New Zealand Clinical Trials Registry, EU Clinical Trials Register, clincialtrials.gov and the OpenGrey Database to 5 January 2020. </p> </section> <section id="CD011033-sec-0004"> <h3 class="title" id="CD011033-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) involving pharmacological agents used in the treatment of Buerger's disease. </p> </section> <section id="CD011033-sec-0005"> <h3 class="title" id="CD011033-sec-0005">Data collection and analysis</h3> <p>Two review authors, independently assessed the studies, extracted data and performed data analysis. </p> </section> <section id="CD011033-sec-0006"> <h3 class="title" id="CD011033-sec-0006">Main results</h3> <p>No new studies were identified for this update. Five randomised controlled trials (total 602 participants) compared prostacyclin analogue with placebo, aspirin, or a prostaglandin analogue, and folic acid with placebo. No studies assessed other pharmacological agents such as cilostazol, clopidogrel and pentoxifylline or compared oral versus intravenous prostanoid. </p> <p>Compared with aspirin, intravenous prostacyclin analogue iloprost improved ulcer healing (risk ratio (RR) 2.65; 95% confidence interval (CI) 1.15 to 6.11; 98 participants; 1 study; moderate‐certainty evidence), and helped to eradicate rest pain after 28 days (RR 2.28; 95% CI 1.48 to 3.52; 133 participants; 1 study; moderate‐certainty evidence), although amputation rates were similar six months after treatment (RR 0.32; 95% CI 0.09 to 1.15; 95 participants; 1 study; moderate‐certainty evidence). </p> <p>When comparing prostacyclin (iloprost and clinprost) with prostaglandin (alprostadil) analogues, ulcer healing was similar (RR 1.13; 95% CI 0.76 to 1.69; 89 participants; 2 studies; I² = 0%; very low‐certainty evidence), as was the eradication of rest pain after 28 days (RR 1.57; 95% CI 0.72 to 3.44; 38 participants; 1 study; low‐certainty evidence), while amputation rates were not measured. </p> <p>Compared with placebo, the effects of oral prostacyclin analogue iloprost were similar for: healing ischaemic ulcers (iloprost 200 mcg: RR 1.11; 95% CI 0.54 to 2.29; 133 participants; 1 study; moderate‐certainty evidence, and iloprost 400 mcg: RR 0.90; 95% CI 0.42 to 1.93; 135 participants; 1 study; moderate‐certainty evidence), eradication of rest pain after eight weeks (iloprost 200 mcg: RR 1.14; 95% CI 0.79 to 1.63; 207 participants; 1 study; moderate‐certainty evidence, and iloprost 400 mcg: RR 1.11; 95% CI 0.77 to 1.59; 201 participants; 1 study; moderate‐certainty evidence), and amputation rates after six months (iloprost 200 mcg: RR 0.54; 95% CI 0.19 to 1.56; 209 participants; 1 study, and iloprost 400 mcg: RR 0.42; 95% CI 0.13 to 1.31; 213 participants; 1 study). </p> <p>When comparing folic acid with placebo in patients with Buerger's disease and hyperhomocysteinaemia, pain scores were similar, there were no new cases of amputation in either group, and ulcer healing was not assessed (very low‐certainty evidence). </p> <p>Treatment side effects such as headaches, flushing or nausea were not associated with treatment interruptions or more serious consequences. Outcomes such as amputation‐free survival, walking distance or pain‐free walking distance, and ankle brachial index were not assessed by any study. </p> <p>Overall, the certainty of the evidence was very low to moderate, with few studies, small numbers of participants, variation in severity of disease of participants between studies and missing information (for example regarding baseline tobacco exposure). </p> </section> <section id="CD011033-sec-0007"> <h3 class="title" id="CD011033-sec-0007">Authors' conclusions</h3> <p>Moderate‐certainty evidence suggests that intravenous iloprost (prostacyclin analogue) is more effective than aspirin for eradicating rest pain and healing ischaemic ulcers in Buerger’s disease, but oral iloprost is not more effective than placebo. Very low and low‐certainty evidence suggests there is no clear difference between prostacyclin (iloprost and clinprost) and the prostaglandin analogue alprostadil for healing ulcers and relieving pain respectively in severe Buerger’s disease. Very low‐certainty evidence suggests there is no clear difference in pain scores and amputation rates between folic acid and placebo, in people with Buerger's disease and hyperhomocysteinaemia. Further well designed RCTs assessing the effectiveness of pharmacological agents (intravenous or oral) in people with Buerger's disease are needed. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD011033-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011033-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011033-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011033-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011033-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/ms#CD011033-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD011033-abs-0010">Polski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD011033-abs-0006">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011033-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD011033-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD011033-abs-0002" lang="en"> <h3>Pharmacological treatment (drugs) for Buerger's disease</h3> <p><b>Background</b> </p> <p>Buerger's disease is characterised by recurring progressive inflammation and clotting in small and medium arteries and veins of the hands and feet. Its cause is unknown, but it is most common in men with a history of tobacco use. It is responsible for ulcers and extreme pain in the limbs of young smokers. In many cases, mainly in patients with the most severe form, there is no possibility of improving the condition with surgery, and therefore, drugs (pharmacological agents) are used. These can be pharmacological agents, such as cilostazol, clopidogrel, and pentoxifylline, or medicine derivatives of prostacyclin and prostaglandin, which redirect blood flow and improve the circulation in affected areas, and might help to heal ulcers and relieve rest pain. This review assessed the effectiveness of pharmacological agents in the treatment of patients with Buerger's disease. </p> <p><b>Key results</b> </p> <p>Our search identified five randomised controlled trials (RCTs), with a total of 602 participants and a treatment period of around four weeks (evidence current until 15 October 2019). The comparisons included prostacyclin analogue versus placebo, aspirin, and a prostaglandin analogue, and folic acid versus placebo. We did not identify studies that assessed pharmacological agents such as cilostazol, clopidogrel and pentoxifylline, or studies that compared oral prostanoid versus prostanoid given intravenously (administered into the vein by injection or infusion). The included studies assessed derivatives of prostacyclin and prostaglandin, which have the ability to redirect blood flow and improve the circulation in affected areas. </p> <p>Moderate‐certainty evidence from one study suggested that intravenous iloprost was effective in healing ulcers and relieving rest pain after 28 days of treatment when compared with oral aspirin, but no clear differences were found in the rates of amputation. Evidence from two studies suggested that prostacyclin was as effective as prostaglandin analogues in healing ulcers (very low‐certainty evidence) and eradicating pain at rest (low‐certainty evidence), but rates of amputation were not assessed. Moderate‐certainty evidence from one study suggested that there was no clear difference between placebo and the oral prostacyclin analogue iloprost (200 mcg and 400 mcg) in healing ischaemic ulcers or eradicating pain at rest after eight weeks and six months, and rates of amputation after six months. Very low‐certainty evidence from one study showed no clear difference between placebo and folic acid, in patients with Buerger's disease and hyperhomocysteinaemia (a medical condition characterised by abnormally high level of homocysteine in the blood), in rates of amputation and pain scores. Ulcer healing was not measured. Treatment side effects, such as headaches or nausea, did not result in treatment interruptions or more serious consequences. Outcomes such as amputation‐free survival, walking distance or pain‐free walking distance, and ankle brachial index were not assessed by any study. </p> <p><b>Certainty of the evidence</b> </p> <p>Overall, the certainty of the evidence was very low to moderate. we downgraded the certainty of the evidence because of the small numbers of studies, small numbers of participants, variation in severity of disease of participants between studies, and missing information (for example baseline tobacco exposure information). Further well designed RCTs assessing the effectiveness of pharmacological agents (intravenous or oral) in people with Buerger's disease are needed. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD011033-sec-0088" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD011033-sec-0088"></div> <h3 class="title" id="CD011033-sec-0089">Implications for practice</h3> <section id="CD011033-sec-0089"> <p>There is moderate‐certainty evidence that intravenous iloprost (prostacyclin analogue) is more effective than aspirin for eradicating rest pain and healing ischaemic ulcers in Buerger’s disease, but oral iloprost is not more effective than placebo. </p> <p>Very low and low‐certainty evidence suggests there is no clear difference between prostacyclin (iloprost and clinprost) and the prostaglandin analogue alprostadil for healing ulcers and relieving pain respectively in severe Buerger’s disease. </p> <p>Very low‐certainty evidence suggests there is no clear difference in pain and rates of amputation between folic acid and placebo in patients with Buerger's disease and hyperhomocysteinaemia. </p> <p>In most cases, treatment side effects such as headaches, flushing or nausea experienced by the participants were not associated with treatment interruptions or more serious consequences. </p> </section> <h3 class="title" id="CD011033-sec-0090">Implications for research</h3> <section id="CD011033-sec-0090"> <p>Further well designed RCTs assessing the effectiveness of pharmacological agents (intravenous or oral) in people with Buerger's disease are needed. We suggest future trials investigating pharmacological treatment of Buerger’s disease should incorporate the following characteristics: </p> <p> <ul id="CD011033-list-0009"> <li> <p>Clearly describe the methods of randomisation and concealment of allocation;</p> </li> <li> <p>Include participants with mild/moderate ischaemia, such as intermittent claudication;</p> </li> <li> <p>Evaluate outcomes, such as walking distance, pain–free walking distance and ankle brachial index; </p> </li> <li> <p>Compare prostacyclin versus prostaglandin analogues;</p> </li> <li> <p>Investigate pharmacological agents for which there currently is no RCT evidence such as pentoxifylline, cilostazol and clopidogrel; </p> </li> <li> <p>Assess pain utilizing validated scores/scales;</p> </li> <li> <p>Assess quality of life using quality of life scales;</p> </li> <li> <p>Evaluate time without amputation (amputation free‐survival);</p> </li> <li> <p>Investigate folic acid reposition in patients with Buerger's disease, hyperhomocysteinaemia and critical limb ischaemia. </p> </li> </ul> </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD011033-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD011033-sec-0008"></div> <div class="table" id="CD011033-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">(Oral or intravenous) prostanoid versus aspirin treatment for Buerger's disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Intravenous prostacyclin analogue (iloprost) versus oral aspirin for treatment of Buerger's disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with Buerger's disease </p> <p><b>Settings:</b> hospital and community </p> <p><b>Intervention:</b> intravenous prostacyclin analogue (iloprost) </p> <p><b>Comparison:</b> oral aspirin </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects * (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with oral aspirin</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with intravenous prostacyclin analogue (iloprost)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Ulcer healing</b> </p> <p>Follow‐up: 28 days</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population (28 days)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 2.65</b> (1.15 to 6.11) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>98<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<sup>1,2</sup><br/><b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>130 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>346 per 1000</b> </p> <p>(150 to 797)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Complete relief of rest pain</b> </p> <p>Follow‐up: 28 days</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 2.28</b> (1.48 to 3.52) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>133<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<sup>1,2</sup><br/><b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>277 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>631 per 1000</b> </p> <p>(410 to 975)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Rate of amputation</b> </p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.32</b> (0.09 to 1.15) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>95</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<sup>1,2</sup><br/><b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>182 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>58 per 1000</b> </p> <p>(16 to 209)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> one single study (doubt about reproducibility of data), downgraded by one level<br/><sup>2</sup> conflict of interest not stated but it was not considered sufficient to downgrade the certainty of evidence </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011033-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Intravenous prostacyclin analogue versus intravenous prostaglandin analogue for treatment of Buerger's disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Intravenous prostacyclin analogue versus intravenous prostaglandin analogue for treatment of Buerger's disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with Buerger's disease </p> <p><b>Settings:</b> hospital and community </p> <p><b>Intervention:</b> intravenous prostacyclin analogue (clinprost, iloprost) </p> <p><b>Comparison:</b> intravenous prostaglandin analogue (alprostadil) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects * (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with intravenous prostaglandin analogue (alprostadil)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with intravenous prostacyclin analogue (clinprost, iloprost)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Ulcer healing</b> </p> <p>Follow‐up: 28 days</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.13</b> (0.76 to 1.69) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>89<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<sup>1,2,3,4</sup><br/><b>very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>480 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>542 per 1000</b> </p> <p>(365 to 811)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>486 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>550 per 1000</b><br/>(370 to 822) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Complete relief of pain</b> </p> <p>Follow‐up: 28 days</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.57</b> (0.72 to 3.44) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>38</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<sup>2,3,5</sup><br/><b>low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>318 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>500 per 1000</b> </p> <p>(229 to 1000)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Rate of amputation</b> </p> <p>Follow‐up: 28 days</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate of amputation was not appraised by the studies in this comparison</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> adoption of 'as‐treated' (per‐protocol) analyses, downgraded by one level<br/><sup>2</sup> absence of patients' smoking history, downgraded by one level<br/><sup>3</sup> conflict of interest not stated but it was not considered sufficient to downgrade the certainty of evidence<br/><sup>4</sup> small number of participants, downgraded by one level<br/><sup>5</sup> one single study (doubt about reproducibility of data), downgraded by one level </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011033-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">(Oral or intravenous) prostanoid versus placebo for treatment of Buerger's disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Oral prostacyclin analogue (iloprost) versus placebo for treatment of Buerger's disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with Buerger's disease </p> <p><b>Settings:</b> hospital and community </p> <p><b>Intervention:</b> oral prostacyclin analogue (iloprost) in two doses: 200 mcg and 400 mcg </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects * (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with oral prostacyclin analogue (iloprost)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Ulcer healing</b> </p> <p>Follow‐up: 8 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population (200 mcg)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.11</b> (0.54 to 2.29) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>133</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<sup>1,2</sup><br/><b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>171 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>190 per 1000</b> </p> <p>(93 to 393)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population (400 mcg)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.90</b> (0.42 to 1.93) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>135</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<sup>1,2</sup><br/><b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>171 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>154 per 1000</b> </p> <p>(72 to 331)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Complete relief of rest pain</b> </p> <p>Follow‐up: 8 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population (200 mcg)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.14</b> (0.79 to 1.63) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>207</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<sup>1,2</sup><br/><b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>343 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>391 per 1000</b> </p> <p>(271 to 559)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population (400 mcg)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.11</b> (0.77 to 1.59) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>210</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<sup>1,2</sup><br/><b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>343 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>381 per 1000</b> </p> <p>(264 to 546)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Rate of amputation</b> </p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population (200 mcg)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.54</b> (0.19 to 1.56) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>209</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<sup>1,2</sup><br/><b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>87 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>47 per 1000</b> </p> <p>(17 to 136)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population (400 mcg)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.42</b> (0.13 to 1.31) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>213</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<sup>1,2</sup><br/><b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>87 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>37 per 1000</b> </p> <p>(11 to 114)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> one single study (doubt about reproducibility of data), downgraded by one level<br/><sup>2</sup> conflict of interest not stated but it was not considered sufficient to downgrade the certainty of evidence </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011033-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Any pharmacological agent versus placebo or any other pharmacological agent for treatment of Buerger's disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Folic acid versus placebo for treatment of Buerger's disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with Buerger's disease<br/><b>Settings:</b> community<br/><b>Intervention:</b> folic acid </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects * (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="table-header separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p>Risk with p<b>lacebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p>Risk with f<b>olic acid</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ulcer healing</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ulcer healing was not appraised by the study in this comparison</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Pain</b> <br/>VAS. Scale from: 0 to 10; higher score = more pain </p> <p>Follow‐up: 0, 2, 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Baseline</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>30<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<sup>1</sup><br/><b>very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pain in the placebo group was<br/><b>5.09 points</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pain in the intervention group was<br/><b>1.17 higher</b><br/>(0.66 lower to 3.00 higher) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>2 months</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>30<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<sup>1</sup><br/><b>very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pain in the placebo group was<br/><b>5.75 points</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pain in the intervention group was<br/><b>0.3 lower</b><br/>(2.04 lower to 1.44 higher) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>6 months</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>30<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<sup>1</sup><br/><b>very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pain in the placebo group was<br/><b>4.82 points</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pain in the intervention group was<br/><b>1.36 lower</b><br/>(3.17 lower to 0.45 higher) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Change in rate of amputation</b> </p> <p>(Difference in number of amputations at start of treatment)</p> <p>Follow‐up: 2 and 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>2 months</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>30<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<sup>1</sup><br/><b>very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No new cases of amputations two months after start of treatment</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>see comment</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>6 months</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>30<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<sup>1</sup><br/><b>very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No new cases of amputations six months after start of treatment</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>see comment</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>MD</b> : mean difference; <b>VAS</b>: visual analogue scale </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> participants without critical ischaemia, resulting in absence of amputations and no differences in pain score in both groups, one single small study ‐ downgraded by three levels </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD011033-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD011033-sec-0009"></div> <section id="CD011033-sec-0010"> <h3 class="title" id="CD011033-sec-0010">Description of the condition</h3> <p>Buerger's disease (thromboangiitis obliterans) is a non‐atherosclerotic, segmental inflammatory pathology that most commonly affects the small and medium sized arteries, veins and nerves in the upper and lower extremities (<a href="./references#CD011033-bbs2-0039" title="OlinJW . Thromboangiitis obliterans (Buerger's disease). New England Journal of Medicine2000;343(12):864-9.">Olin 2000</a>). Von Winiwarter first described a patient with the disease in 1879 (<a href="./references#CD011033-bbs2-0046" title="vonWiniwarterF . A peculiar form of endarteritis and endophlebitis with gangrene of the foot [Ueber eine eigenthümliche Form von Endarteriitis und Endophlebitis mit Gangrän des Fusses]. Archiv für Klinische Chirurgie1879;23:202-26.">von Winiwarter 1879</a>), but it was Leo Buerger, in 1908, who published a detailed description of the pathological findings on amputated limbs and named the disease (<a href="./references#CD011033-bbs2-0020" title="BuergerL . Thrombo-angiitis obliterans: a study of the vascular lesions leading to presenile spontaneous gangrene. American Journal of Medicine1908;136:567-80.">Buerger 1908</a>). </p> <p>The prevalence of the disease among all patients with peripheral arterial disease (PAD) varies from as low as 0.5% to 5.6% in Western Europe to as high as 45% to 63% in India, and 16% to 66% in Korea and Japan (<a href="./references#CD011033-bbs2-0021" title="CachovanM . Epidemiology and geographic distribution of the thromboangiitis obliterans [Epidemiologic und geographisches Verteilungsmuster der thromboangiitis obliterans]. In: Thromboangiitis obliterans Morbus Winiwarter-Buerger. Heidrich H. Stuttgart, 1988:31-6.">Cachovan 1988</a>; <a href="./references#CD011033-bbs2-0036" title="MaleckiR , ZdrojowyK , AdamiecR . Thromboangiitis obliterans in the 21st century - a new face of disease. Atherosclerosis2009;206(2):328-34.">Malecki 2009</a>; <a href="./references#CD011033-bbs2-0039" title="OlinJW . Thromboangiitis obliterans (Buerger's disease). New England Journal of Medicine2000;343(12):864-9.">Olin 2000</a>). </p> <p>The etiology is unknown, but involves hereditary susceptibility, tobacco exposure, immune and coagulation responses (<a href="./references#CD011033-bbs2-0036" title="MaleckiR , ZdrojowyK , AdamiecR . Thromboangiitis obliterans in the 21st century - a new face of disease. Atherosclerosis2009;206(2):328-34.">Malecki 2009</a>). Currently, a possible infectious etiology is gaining interest, especially after the findings of micro‐organisms of the oral flora in occlusive thrombi in patients with Buerger's disease and moderate to severe periodontitis (<a href="./references#CD011033-bbs2-0032" title="IwaiT , InoueY , UmedaM , HuangY , KuriharaN , KoikeM , et al. Oral bacteria in the occluded arteries of patients with Buerger disease. Journal of Vascular Surgery2005;42(1):107-15.">Iwai 2005</a>; <a href="./references#CD011033-bbs2-0035" title="LiX , IwaiT , NakamuraH , InoueY , ChenY , UmedaM , et al. An ultrastructural study of Porphyromonas gingivalis-induced platelet aggregation. Thrombosis Research2008;122(6):810-9.">Li 2008</a>). Another hypothesis is the possible pathogenic role of rickettsial infection in Buerger's disease (<a href="./references#CD011033-bbs2-0017" title="BartoloM , AntignaniPL , TodiniAR , RicciG . Buerger's disease: etiologic role of the rickettsiae?Journal des Maladies Vasculaires1987;12(1):82-4.">Bartolo 1987</a>; <a href="./references#CD011033-bbs2-0026" title="FazeliB . Is rickettsia the key to solving the puzzle of Buerger’s disease?Vascular2013;22(5):393-4.">Fazeli 2013</a>). Features distinguishing Buerger's disease from atherosclerosis include the pathology distribution (with involvement of both the upper and lower extremities), associated superficial venous thrombosis, a paucity of atherosclerotic risk factors and normal proximal large arteries (<a href="./references#CD011033-bbs2-0048" title="WeinbergI , JaffMR . Nonatherosclerotic arterial disorders of the lower extremities. Circulation2012;126(2):213-22.">Weinberg 2012</a>). </p> <section id="CD011033-sec-0011"> <h4 class="title">Diagnosis and complications</h4> <p>The typical patient with Buerger's disease is a young man (younger than 40 or 45 years) with a history of tobacco use, who presents with progressive claudication, ischaemic ulcers, or pain at rest (<a href="./references#CD011033-bbs2-0039" title="OlinJW . Thromboangiitis obliterans (Buerger's disease). New England Journal of Medicine2000;343(12):864-9.">Olin 2000</a>); approximately 76% of patients have ischaemic ulcerations at the time of presentation (<a href="./references#CD011033-bbs2-0040" title="OlinJW , ShihA . Thromboangiitis obliterans (Buerger’s disease). Current Opinion in Rheumatology2006;18(1):18-24.">Olin 2006</a>). To date, there are no unanimous diagnostic criteria for Buerger's disease. The most commonly used are Shionoya's criteria, which comprise: (1) smoking history; (2) onset of symptoms before the age of 50 years; (3) infrapopliteal arterial occlusions; (4) either arm involvement or phlebitis migrans; and (5) absence of atherosclerotic risk factors other than smoking (<a href="./references#CD011033-bbs2-0045" title="ShionoyaS . What is Buerger's disease?World Journal of Surgery1983;7(4):544-51.">Shionoya 1983</a>). All criteria should be present. The disease is usually confined to the distal circulation and is almost always infrapopliteal in the legs and distal to the brachial artery in the arms (<a href="./references#CD011033-bbs2-0039" title="OlinJW . Thromboangiitis obliterans (Buerger's disease). New England Journal of Medicine2000;343(12):864-9.">Olin 2000</a>). In fact, the distal and diffuse nature of the disease culminates in critical limb ischaemia (CLI) in approximately 76% to 81% of patients, with poor chances of revascularisation (<a href="./references#CD011033-bbs2-0040" title="OlinJW , ShihA . Thromboangiitis obliterans (Buerger’s disease). Current Opinion in Rheumatology2006;18(1):18-24.">Olin 2006</a>). In patients diagnosed with limb ischaemia, as in Buerger's disease, the clinical evaluation is done according to the Rutherford classification and the Fontaine stages. The Rutherford classification for PAD has seven categories. These are: (0) asymptomatic; (1) mild claudication; (2) moderate claudication; (3) severe claudication; (4) rest pain; (5) minor tissue loss, non‐healing ulcer or focal gangrene with diffuse pedal ischaemia; (6) major tissue loss extending above the transmetatarsal level; and (7) a functional foot that is no longer salvageable (<a href="./references#CD011033-bbs2-0043" title="RutherfordRB . Vascular Surgery. 6th edition. Vol. 1. New York: Elsevier Inc, 2005.">Rutherford 2005</a>). The Fontaine classification has four stages: (I) asymptomatic; (II) intermittent claudication (IC); (III) rest pain; (IV) ulceration or gangrene, or both (<a href="./references#CD011033-bbs2-0028" title="FontaineR , KimM , KienyR . Surgical treatment of peripheral circulation disorders [Die chirugische Behandlung der peripheren Durchblutungsstörungen]. Helvetica Chirurgica Acta1954;21(5/6):499-533.">Fontaine 1954</a>). <a href="./references#CD011033-bbs2-0038" title="NovoS , CoppolaG , MilioG . Critical limb ischemia: definition and natural history. Current Drug Targets2004;4(3):219-25.">Novo 2004</a> described a modified Fontaine classification, the Leriche‐Fontaine classification: (I) asymptomatic or effort pain; (IIA) effort pain or pain‐free walking distance further than 200 metres; (IIB) pain‐free walking distance less than 200 metres; (IIIA) rest pain, ankle arterial pressure higher than 50 mm Hg; (IIIB) rest pain, ankle arterial pressure lower than 50 mm Hg; (IV) trophic lesions, necrosis or gangrene (<a href="./references#CD011033-bbs2-0038" title="NovoS , CoppolaG , MilioG . Critical limb ischemia: definition and natural history. Current Drug Targets2004;4(3):219-25.">Novo 2004</a>). According to <a href="./references#CD011033-bbs2-0023" title="CooperLT , TseTS , MikhailMA , McBaneRD , StansonAW , BallmanKV . Long-term survival and amputation risk in thromboangiitis obliterans (Buerger's disease). Journal of the American College of Cardiology2004;44(12):2410-1.">Cooper 2004</a>, the risk of any extremity amputation during 15.6 years of follow‐up in patients with Buerger's disease is 25% at five years, 38% at 10 years and 46% at 20 years. </p> </section> </section> <section id="CD011033-sec-0012"> <h3 class="title" id="CD011033-sec-0012">Description of the intervention</h3> <p>In patients with CLI and poor chances of revascularisation, as seen in many patients diagnosed with Buerger's disease, pharmacological treatment is given to improve the blood flow (perfusion) in the affected extremity. The most commonly used pharmacological agents are aspirin, cilostazol (<a href="./references#CD011033-bbs2-0018" title="BedenisR , StewartM , CleanthisM , RoblessP , MikhailidisDP , StansbyG . Cilostazol for intermittent claudication. Cochrane Database of Systematic Reviews2014, Issue 10. [DOI: 10.1002/14651858.CD003748.pub4]">Bedenis 2014</a>; <a href="./references#CD011033-bbs2-0042" title="RuffoloAJ , RomanoM , CiapponiA . Prostanoids for critical limb ischaemia. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD006544.pub2]">Ruffolo 2010</a>), prostanoids (<a href="./references#CD011033-bbs2-0036" title="MaleckiR , ZdrojowyK , AdamiecR . Thromboangiitis obliterans in the 21st century - a new face of disease. Atherosclerosis2009;206(2):328-34.">Malecki 2009</a>), and bosentan (<a href="./references#CD011033-bbs2-0024" title="De HaroJ , FlorezA , FernadezJL , AcinF . Treatment of Buerger disease (thromboangiitis obliterans) with bosentan: a case report. BMJ Case Reports2009. [DOI: 10.1136/bcr.08.2008.0691]">De Haro 2009</a>). </p> <p>Aspirin is a drug that inhibits cyclo‐oxygenase, which is responsible for the synthesis of thromboxane and prostaglandins. It is important in cardiac and cerebrovascular atherosclerotic diseases, as it inhibits platelet aggregation. The most important contraindications are hypersensitivity to salicylates, active gastrointestinal ulcers, patients with hemorrhagic disorders, renal and hepatic failure, pregnancy and use in children. Aspirin is administered orally with a recommended dosage of 75 to 325 mg (<a href="./references#CD011033-bbs2-0019" title="BruntonLL , ChabnerBA , Knollmann BC (editors). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 12th edition. New York: McGraw-Hill Companies, 2011.">Brunton 2011</a>). </p> <p>Cilostazol is a quinolinone derivative drug that inhibits cellular phosphodiesterase (more specific for phosphodiesterase III), affecting both vascular beds and cardiovascular function. It causes a non‐homogeneous dilation of vascular beds, with greater dilation in the femoral beds than in vertebral, carotid or superior mesenteric arteries. In other words, cilostazol 'steals' a small part of the blood from other territories (gastrointestinal and cerebral) to improve perfusion in ischaemic limbs. A further action of cilostazol is the reversible inhibition of platelet aggregation. Cilostazol is contraindicated in patients with congestive heart failure (CHF) of any severity, haemostatic disorders or active pathologic bleeding, such as bleeding peptic ulcer and intracranial bleeding, and in patients with known or suspected hypersensitivity to cilostazol. The more common side effects of cilostazol use include headaches, diarrhoea, abnormal stools and palpitations (<a href="./references#CD011033-bbs2-0022" title="ChapmanTM , GoaKL . Cilostazol: a review of its use in intermittent claudication. American Journal of Cardiovascular Drugs2003;3(2):117-38.">Chapman 2003</a>). Cilostazol is administered orally and is available in 50 mg or 100 mg tablets. Cilostazol was approved by the US Food and Drug Administration (FDA) in 1999 for the reduction of symptoms of intermittent claudication as a result of atherosclerosis (<a href="./references#CD011033-bbs2-0025" title="DindyalS , KyriakidesC . A review of cilostazol, a phosphodiesterase inhibitor, and its role in preventing both coronary and peripheral arterial restenosis following endovascular therapy. Recent Patents on Cardiovascular Drug Discovery2009;4(1):6-14.">Dindyal 2009</a>; <a href="./references#CD011033-bbs2-0027" title="US Food and Drug Administration. FDA approved drug products. /www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search. DrugDetails (accessed 25 November 2015).">FDA 1999</a>). </p> <p>Prostanoids (prostaglandin and prostacyclin analogues) are eicosanoid derivatives, commonly used for many conditions including pulmonary hypertension, sexual impotence, and glaucoma. Because of their short half‐life, around two to three minutes, these synthetic drugs must be administrated by continuous intravenous infusion (<a href="./references#CD011033-bbs2-0044" title="SafdarZ . Treatment of pulmonary arterial hypertension: the role of prostacyclin and prostaglandin analogs. Respiratory Medicine2011;105(6):818-27.">Safdar 2011</a>). The development of stable prostacyclin analogues (such as iloprost) with a longer half‐life has allowed the oral use of these drugs. The most important contraindications are heart failure (caused by arrhythmias, myocardiopathy, valvulopathy, or coronary insufficiency), intracranial haemorrhage, gastrointestinal ulcers, and trauma. Side effects include headache, flushing, malaise, gastrointestinal distress and, with higher doses, hypotension. The maximum iloprost dose that is administered is around 2 ng/kg/min by continuous infusion (<a href="./references#CD011033-bbs2-0030" title="GrantSM , GoaKL . Iloprost. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peripheral vascular disease, myocardial ischaemia and extracorporeal circulation procedures. Drugs1992;43(6):889-924.">Grant 1992</a>). </p> <p>Bosentan is a potent and mixed endothelin‐A and endothelin‐B receptor antagonist, causing selective vasodilatory effects (<a href="./references#CD011033-bbs2-0047" title="WeberC , SchmittR , BirnboeckH , HopfgartnerG , vanMarleSP , PeetersPAM , et al. Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentanin healthy human subjects. Clinical Pharmacology and Therapeutics1996;60:124-37.">Weber 1996</a>). Some important reported side effects are hepatotoxicity and fluid retention. Bosentan is administered orally, mainly in patients with pulmonary arterial hypertension, with a recommended dosage of 62.5 mg (twice daily) to 125 mg (twice daily). </p> </section> <section id="CD011033-sec-0013"> <h3 class="title" id="CD011033-sec-0013">How the intervention might work</h3> <p>Aspirin (acetylsalicylic acid), a thromboxane production inhibitor, is well‐known as an antiplatelet drug, and is used in heart attack and stroke prevention (<a href="./references#CD011033-bbs2-0019" title="BruntonLL , ChabnerBA , Knollmann BC (editors). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 12th edition. New York: McGraw-Hill Companies, 2011.">Brunton 2011</a>). </p> <p>Cilostazol, a selective inhibitor of phosphodiesterase III, is used mainly in patients with IC, and acts as a direct arterial vasodilatator and inhibits platelet aggregation (<a href="./references#CD011033-bbs2-0043" title="RutherfordRB . Vascular Surgery. 6th edition. Vol. 1. New York: Elsevier Inc, 2005.">Rutherford 2005</a>). </p> <p>Prostanoids act by binding to specific receptors in the endothelium (causing vasodilatation) and platelets (inhibiting platelet aggregation), which causes a transitory increase in arterial peripheral perfusion (<a href="./references#CD011033-bbs2-0019" title="BruntonLL , ChabnerBA , Knollmann BC (editors). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 12th edition. New York: McGraw-Hill Companies, 2011.">Brunton 2011</a>). Arterial vasodilatation in ischaemic areas increases blood perfusion and, consequently, increases the chances of ulcer healing and improving rest pain. Inhibiting platelet aggregation prevents the occlusion of small arteries and, therefore, stabilizes the disease. </p> <p>Bosentan, a potent and mixed endothelin‐A and endothelin‐B receptor antagonist, causes selective vasodilatory effects (<a href="./references#CD011033-bbs2-0047" title="WeberC , SchmittR , BirnboeckH , HopfgartnerG , vanMarleSP , PeetersPAM , et al. Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentanin healthy human subjects. Clinical Pharmacology and Therapeutics1996;60:124-37.">Weber 1996</a>). Bosentan has been used with success in patients with digital ulcers and systemic sclerosis (<a href="./references#CD011033-bbs2-0033" title="LaunayD , DiotE , PasquierE , MouthonL , BoullangerN , FainO , et al. Bosentan for treatment of active digital ulcers in patients with systemic sclerosis. La Presse Médicale2006;35(4 Pt 1):587-92.">Launay 2006</a>; <a href="./references#CD011033-bbs2-0037" title="Matucci-CerinicM , DentonCP , FurstDE , MayesMD , HsuVM , CarpentierP , et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Annals of the Rheumatic Diseases2011;70(1):32-8.">Matucci‐Cerinic 2011</a>), opening the perspective for use in other conditions such as Buerger's disease (<a href="./references#CD011033-bbs2-0024" title="De HaroJ , FlorezA , FernadezJL , AcinF . Treatment of Buerger disease (thromboangiitis obliterans) with bosentan: a case report. BMJ Case Reports2009. [DOI: 10.1136/bcr.08.2008.0691]">De Haro 2009</a>). </p> <p>Therefore, these pharmacological agents are used to improve perfusion in ischaemic limbs due to their vasodilatatory and antiplatelet effects. The effects may vary from agent to agent. </p> </section> <section id="CD011033-sec-0014"> <h3 class="title" id="CD011033-sec-0014">Why it is important to do this review</h3> <p>Buerger's disease is a debilitating condition which can affect active, young people. In many cases, there is possibility of revascularisation to improve the condition. Different combinations of drugs, doses and administration pathways (oral and intravenously) have been approved for use. However, to date there is no consensus about the best pharmacological treatment for patients with Buerger's disease. A systematic review is opportune and extremely relevant. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD011033-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD011033-sec-0015"></div> <p>To assess the effectiveness of any pharmacological agent (intravenous or oral) compared with placebo or any other pharmacological agent in patients with Buerger's disease. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD011033-sec-0016" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD011033-sec-0016"></div> <section id="CD011033-sec-0017"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD011033-sec-0018"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials (RCTs) involving pharmacological agents used in the treatment of Buerger's disease. </p> </section> <section id="CD011033-sec-0019"> <h4 class="title">Types of participants</h4> <p>We included patients clinically diagnosed with Buerger's disease.</p> </section> <section id="CD011033-sec-0020"> <h4 class="title">Types of interventions</h4> <p>We assessed any pharmacological agents used in treating patients with Buerger's disease, including drugs utilized for atherosclerotic diseases, such as aspirin or cilostazol, resulting in the possible comparisons listed below: </p> <p> <ul id="CD011033-list-0001"> <li> <p>(Oral or intravenous) prostanoid (e.g. iloprost) versus placebo</p> </li> <li> <p>Oral prostanoid versus intravenous prostanoid</p> </li> <li> <p>(Oral or intravenous) prostanoid (e.g. iloprost) versus aspirin</p> </li> <li> <p>(Oral or intravenous) prostanoid (e.g. iloprost) versus cilostazol</p> </li> <li> <p>Aspirin versus placebo</p> </li> <li> <p>Cilostazol versus placebo</p> </li> <li> <p>Aspirin versus cilostazol</p> </li> <li> <p>Any pharmacological agent versus placebo or any other pharmacological agent</p> </li> </ul> </p> <p>Prostanoids could be either prostaglandin or prostacyclin analogues. We excluded studies that did not assess pharmacological agents in the treatment of Buerger's disease. </p> </section> <section id="CD011033-sec-0021"> <h4 class="title">Types of outcome measures</h4> <section id="CD011033-sec-0022"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD011033-list-0002"> <li> <p>Ulcer healing</p> </li> <li> <p>Pain: assessed using a validated pain score or scale, or quality of life (QoL) questionnaire</p> </li> <li> <p>Rate of amputation: major amputation (defined as amputation of the lower or upper limb above the ankle or the wrist, respectively); and minor amputation (defined as amputation of a hand or foot or any part of) </p> </li> </ul> </p> </section> <section id="CD011033-sec-0023"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD011033-list-0003"> <li> <p>Amputation‐free survival</p> </li> <li> <p>Side effects of pharmacological agents, including bleeding, headache, flushing, or nausea </p> </li> <li> <p>Walking distance or pain‐free walking</p> </li> <li> <p>Ankle brachial index</p> </li> </ul> </p> </section> </section> </section> <section id="CD011033-sec-0024"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD011033-sec-0025"> <h4 class="title">Electronic searches</h4> <p>The Cochrane Vascular Information Specialist conducted systematic searches of the following databases for randomised controlled trials and controlled clinical trials without language, publication year or publication status restrictions: </p> <p> <ul id="CD011033-list-0004"> <li> <p>the Cochrane Vascular Specialised Register via the Cochrane Register of Studies (CRS‐Web searched on 15 October 2019); </p> </li> <li> <p>the Cochrane Central Register of Controlled Trials (CENTRAL) Cochrane Register of Studies Online (CRSO 2019, Issue 10); </p> </li> <li> <p>MEDLINE (Ovid MEDLINE® Epub Ahead of Print, In‐Process &amp; Other Non‐Indexed Citations, Ovid MEDLINE® Daily and Ovid MEDLINE®) (searched from 1 January 2015 to 15 October 2019); </p> </li> <li> <p>Embase Ovid (searched from 1 January 2015 to 15 October 2019);</p> </li> <li> <p>CINAHL Ebsco (searched from 1 January 2015 to 15 October 2019);</p> </li> <li> <p>AMED Ovid (searched from 1 January 2015 to 15 October 2019).</p> </li> </ul> </p> <p>The Information Specialist modelled search strategies for other databases on the search strategy designed for CENTRAL. Where appropriate, they were combined with adaptations of the highly sensitive search strategy designed by the Cochrane Collaboration for identifying randomised controlled trials and controlled clinical trials (as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> Chapter 6, <a href="./references#CD011033-bbs2-0034" title="LefebvreC , ManheimerE , GlanvilleJ . Chapter 6: Searching for studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Lefebvre 2011</a>). Search strategies for major databases are provided in <a href="./appendices#CD011033-sec-0094">Appendix 1</a>. </p> <p>The Information Specialist searched the following trials registries on 15 October 2019: </p> <p> <ul id="CD011033-list-0005"> <li> <p>the World Health Organization International Clinical Trials Registry Platform (<a href="https://apps.who.int/trialsearch/" target="_blank">who.int/trialsearch</a>); </p> </li> <li> <p>ClinicalTrials.gov (<a href="https://clinicaltrials.gov/" target="_blank">clinicaltrials.gov</a>). </p> </li> </ul> </p> <p>We, the review authors, also searched the following trial registers and databases (searched from 10 May 2015 to 5 January 2020). Search strategies used are provided in <a href="./appendices#CD011033-sec-0095">Appendix 2</a>. </p> <p> <ul id="CD011033-list-0006"> <li> <p>ISRCTN register (<a href="http://www.isrctn.com" target="_blank">isrctn.com</a>); </p> </li> <li> <p>ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov/" target="_blank">clinicaltrials.gov</a>); </p> </li> <li> <p>The Australian New Zealand Clinical Trials Registry (<a href="http://www.anzctr.org.au/" target="_blank">anzctr.org.au</a>); </p> </li> <li> <p>The EU Clinical Trials Register (<a href="http://www.clinicaltrialsregister.eu/" target="_blank">clinicaltrialsregister.eu</a>); </p> </li> <li> <p>LILACS, Latin American and Caribbean Health Sciences Literature (<a href="http://lilacs.bvsalud.org/" target="_blank">lilacs.bvsalud.org/</a>). </p> </li> </ul> </p> </section> <section id="CD011033-sec-0026"> <h4 class="title">Searching other resources</h4> <p>We also searched the grey literature produced in Europe by consulting the OpenGrey Database (<a href="http://www.opengrey.eu" target="_blank">opengrey.eu</a>). We used the terms 'Buerger's disease'; 'thromboangiitis obliterans'; 'von Winiwarter disease'; and word variations to perform the search (searched on 5 January 2020). </p> <p>We searched the reference lists of relevant articles retrieved by the electronic searches for additional citations. </p> </section> </section> <section id="CD011033-sec-0027"> <h3 class="title" id="CD011033-sec-0027">Data collection and analysis</h3> <section id="CD011033-sec-0028"> <h4 class="title">Selection of studies</h4> <p>Two of three review authors (DGC, FCN and JCCBS) independently assessed all studies that were identified by the search strategy for inclusion. Disagreements were resolved by a third author (CM). </p> </section> <section id="CD011033-sec-0029"> <h4 class="title">Data extraction and management</h4> <p>For all eligible studies, two of three review authors (DGC, FCN and JCCBS) extracted data using the Cochrane Vascular's data extraction table. Where there were discrepancies, a third author (CM) solved disagreement. We entered the data into Review Manager 5 (<a href="./references#CD011033-bbs2-0041" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager 2014</a>). </p> </section> <section id="CD011033-sec-0030"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (DGC and JCCBS) independently assessed the included studies for risk of bias using Cochrane's 'Risk of bias' tool as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011033-bbs2-0031" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>). The information about the risk of bias of the included studies was presented in the form of a table and a graph. </p> </section> <section id="CD011033-sec-0031"> <h4 class="title">Measures of treatment effect</h4> <section id="CD011033-sec-0032"> <h5 class="title">Dichotomous (categorical) data</h5> <p>Results were presented as summary risk ratios (RR) with 95% confidence intervals (CIs).</p> </section> <section id="CD011033-sec-0033"> <h5 class="title">Continuous data</h5> <p>We had planned to use the mean difference (MD) with 95% CI where there was consistency in the outcome measure, or the standardised mean difference (SMD) to combine trials that measured the same outcome but used different methods. </p> </section> <section id="CD011033-sec-0034"> <h5 class="title">Time‐to‐event data</h5> <p>We had planned to use hazard ratios (HR) with 95% CIs to measure the treatment effect for any time‐to‐event outcomes. </p> </section> </section> <section id="CD011033-sec-0035"> <h4 class="title">Unit of analysis issues</h4> <p>We considered the individual participant as the unit of randomisation for a single intervention. </p> </section> <section id="CD011033-sec-0036"> <h4 class="title">Dealing with missing data</h4> <p>We contacted the contact authors of included studies with any methodological queries, but we did not receive any response. Where possible, we had planned to analyse all outcome measures on an intention‐to‐treat basis by including data from all participants. </p> </section> <section id="CD011033-sec-0037"> <h4 class="title">Assessment of heterogeneity</h4> <p>The heterogeneity among the eligible studies was quantified using the Chi² test and I² statistic, specifically using the formula I² = (Q ‐ df/Q) X 100% where Q was the Chi² statistic and df represented the degree of freedom. The I² statistic values were interpreted as follows: </p> <p> <ul id="CD011033-list-0007"> <li> <p>0% to 25% = low heterogeneity;</p> </li> <li> <p>25% to 75% = moderate heterogeneity;</p> </li> <li> <p>more than 75% = substantial heterogeneity (<a href="./references#CD011033-bbs2-0031" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>). </p> </li> </ul> </p> <p>We planned to perform a further investigation based on the pre‐specified subgroup analysis where substantial heterogeneity was detected, according to the criteria above. </p> </section> <section id="CD011033-sec-0038"> <h4 class="title">Assessment of reporting biases</h4> <p>We planned to explore publication bias through the use of funnel plots and to explore the presence of time‐lag bias in both published and unpublished trials if sufficient eligible trials had been available. As a result of the small number of included studies (five RCTs), these analyses were not performed. </p> </section> <section id="CD011033-sec-0039"> <h4 class="title">Data synthesis</h4> <p>We performed data synthesis using Review Manager 5 (<a href="./references#CD011033-bbs2-0041" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager 2014</a>). After assessing heterogeneity, we had planned to use a random‐effects model of meta‐analysis if substantial heterogeneity between studies was detected. A fixed‐effect model meta‐analysis was planned if the studies estimated the same intervention effect and had low or moderate heterogeneity (<a href="./references#CD011033-bbs2-0031" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>). </p> </section> <section id="CD011033-sec-0040"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We intended to perform subgroup analyses according to the following features if sufficient information had been available: </p> <p> <ul id="CD011033-list-0008"> <li> <p>tobacco exposure (cigarette, cannabis, or any other form of smoking, either measured in a laboratory or declared) after the intervention; </p> </li> <li> <p>severity of the ischaemia, according to the Fontaine or Rutherford classification;</p> </li> <li> <p>different doses of the pharmacological agents.</p> </li> </ul> </p> </section> <section id="CD011033-sec-0041"> <h4 class="title">Sensitivity analysis</h4> <p>We had intended to perform sensitivity analyses by looking separately at sponsored studies and publication bias, and by excluding studies with low and moderate methodological quality according to the 'Risk of bias' judgements. As a result of the small number of studies included for each comparison and a meta‐analysis with only two studies, sensitivity analyses were not performed. </p> </section> <section id="CD011033-sec-0042"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We presented the main findings of the review in 'Summary of findings' tables. We included judgements for the certainty of evidence, the magnitude of effect of the interventions examined, and the sum of available data for the primary outcomes (see <a href="#CD011033-sec-0021">Types of outcome measures</a>) according to <a href="./references#CD011033-bbs2-0031" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a> and the GRADE Working group (<a href="./references#CD011033-bbs2-0016" title="AtkinsD , BestD , BrissPA , EcclesM , Falck-YtterY , FlottorpS , et al. Grading quality of evidence and strength of recommendations. BMJ2004;328(7454):1490-4.">Atkins 2004</a>). Since we assessed different intervention comparisons, a 'Summary of findings' table was developed for each comparison included in the Results section: (Oral or intravenous) prostanoid versus aspirin for treatment of Buerger's disease (<a href="./full#CD011033-tbl-0001">summary of findings Table 1</a>); Intravenous prostacyclin analogue versus intravenous prostaglandin analogue for treatment of Buerger's disease (<a href="./full#CD011033-tbl-0002">summary of findings Table 2</a>); (Oral or intravenous) prostanoid versus placebo for treatment of Buerger's disease (<a href="./full#CD011033-tbl-0003">summary of findings Table 3</a>); and Any pharmacological agent versus placebo or any other pharmacological agent for treatment of Buerger's disease (<a href="./full#CD011033-tbl-0004">summary of findings Table 4</a>). We used GRADEpro software (<a href="./references#CD011033-bbs2-0029" title="McMaster University (developed by Evidence Prime)GRADEpro GDT. Version accessed 15 November 2019. Hamilton (ON): McMaster University (developed by Evidence Prime).Available at gradepro.org.">GRADEpro GDT 2015</a>), to assist in the preparation of the 'Summary of findings' tables. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD011033-sec-0043" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD011033-sec-0043"></div> <section id="CD011033-sec-0044"> <h3 class="title">Description of studies</h3> <p>See <a href="./references#CD011033-sec-0110" title="">Characteristics of included studies</a>, <a href="./references#CD011033-sec-0111" title="">Characteristics of excluded studies</a> and Characteristics of studies awaiting classification tables. </p> <section id="CD011033-sec-0045"> <h4 class="title">Results of the search</h4> <p>A flow diagram of the search results is shown in <a href="#CD011033-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD011033-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD011033-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/image_n/nCD011033-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD011033-sec-0046"> <h4 class="title">Included studies</h4> <p>No new studies were identified for this update. Five randomised controlled studies were included in this review, with a combined total of 602 participants (<a href="./references#CD011033-bbs2-0001" title="BeigiAA , HoghoughiMA , EshaghianA , ZadeAH , MasoudpourH . The role of folic acid on the hyperhomocysteinemia in the Buerger's disease (thromboangiitis obliterans). Journal of Research in Medical Sciences2014;19:1034-7. ">Beigi 2014</a>; <a href="./references#CD011033-bbs2-0002" title="EsatoK , YasudaK , AbeT , HoshinoS , IshimaruS , HoriG , et al. Studies on the clinical efficacy and safety of TTC-909 in the treatment of peripheral arterial occlusive disease: a multi-center double-blind comparison with Alprostadil incorporated in lipid microspheres. Rinsho Iyaku1995;11:2111-2. ">Esato 1995</a>; <a href="./references#CD011033-bbs2-0003" title="DiehmC . Multicenter-study on Iloprost in patients with thromboangiitis obliterans (Buerger's disease). Klinische Wochenschrift1989;67:178-9. FiessingerJN , SchaferM . Trial of iloprost versus aspirin treatment for critical limb ischaemia of thromboangiitis obliterans. Lancet1990;335(8689):555-7. ">Fiessinger 1990</a>; <a href="./references#CD011033-bbs2-0004" title="IshitobiK , et al. Therapeutic efficacy of iloprost, a prostacyclin analogue for chronic arterial occlusion: a double-blind comparative study with PGE1. Rinsho to Kenkyu1991;68:1836-50. ">Ishitobi 1991</a>; <a href="./references#CD011033-bbs2-0005" title="VerstraeteM . Oral iloprost in the treatment of thromboangiitis obliterans (Buerger's disease): a double-blind, randomised, placebo-controlled trial. The European TAO Study Group. European Journal of Vascular and Endovascular Surgery1998;15(4):300-7. ">Verstraete 1998</a>). </p> <p><a href="./references#CD011033-bbs2-0001" title="BeigiAA , HoghoughiMA , EshaghianA , ZadeAH , MasoudpourH . The role of folic acid on the hyperhomocysteinemia in the Buerger's disease (thromboangiitis obliterans). Journal of Research in Medical Sciences2014;19:1034-7. ">Beigi 2014</a> reported on a study of 30 participants with Buerger's disease (Fontaine II of ischaemia) and hyperhomocysteinaemia (a well known and established risk factor for limb ischaemia in patients with atherosclerosis), who were receiving folic acid or placebo (single dose); they compared the number of major and minor amputations and pain in both groups. </p> <p>In <a href="./references#CD011033-bbs2-0002" title="EsatoK , YasudaK , AbeT , HoshinoS , IshimaruS , HoriG , et al. Studies on the clinical efficacy and safety of TTC-909 in the treatment of peripheral arterial occlusive disease: a multi-center double-blind comparison with Alprostadil incorporated in lipid microspheres. Rinsho Iyaku1995;11:2111-2. ">Esato 1995</a>, 46 participants with Buerger's disease received a prostacyclin analogue (clinprost) or a prostaglandin analogue (alprostadil) for four weeks; they compared improvements in ischaemic ulcers and rest pain. </p> <p><a href="./references#CD011033-bbs2-0003" title="DiehmC . Multicenter-study on Iloprost in patients with thromboangiitis obliterans (Buerger's disease). Klinische Wochenschrift1989;67:178-9. FiessingerJN , SchaferM . Trial of iloprost versus aspirin treatment for critical limb ischaemia of thromboangiitis obliterans. Lancet1990;335(8689):555-7. ">Fiessinger 1990</a> reported on a European multicentre randomised study that included 152 participants with Buerger's disease, in critical limb ischaemia (rest pain, ulcers or gangrene), who were receiving prostacyclin analogue (iloprost endovenously) or aspirin orally for 28 days. </p> <p><a href="./references#CD011033-bbs2-0004" title="IshitobiK , et al. Therapeutic efficacy of iloprost, a prostacyclin analogue for chronic arterial occlusion: a double-blind comparative study with PGE1. Rinsho to Kenkyu1991;68:1836-50. ">Ishitobi 1991</a> was a trial of 134 participants with critical limb ischaemia, which included 55 participants diagnosed with Buerger's disease. The pharmacological treatment assessed the efficacy between a prostaglandin analogue (alprostadil) and a prostacyclin analogue (iloprost), both of them administered intravenously for 28 days. </p> <p><a href="./references#CD011033-bbs2-0005" title="VerstraeteM . Oral iloprost in the treatment of thromboangiitis obliterans (Buerger's disease): a double-blind, randomised, placebo-controlled trial. The European TAO Study Group. European Journal of Vascular and Endovascular Surgery1998;15(4):300-7. ">Verstraete 1998</a> described a large multicentre randomised trial with 319 participants with Buerger's disease with rest pain, ischaemic ulcers, or both, who were administered a prostaglandin analogue (iloprost) orally or placebo for eight weeks, with a six‐month follow‐up. </p> <p>No studies were identified that compared oral prostanoid and intravenous prostanoid, (oral or intravenous) prostanoid (e.g. iloprost) and cilostazol, aspirin and placebo, cilostazol and placebo, and aspirin and cilostazol. </p> </section> <section id="CD011033-sec-0047"> <h4 class="title">Excluded studies</h4> <p>Ten studies were excluded (<a href="./references#CD011033-bbs2-0006" title="BozkurtAK , KoksalC , DemirbasMY , ErdoganA , RahmanA , DemirkilicU , et al. A randomized trial of intravenous iloprost (a stable prostacyclin analogue) versus lumbar sympathectomy in the management of Buerger's disease. International Angiology2006;25:162-8. ">Bozkurt 2006</a>; <a href="./references#CD011033-bbs2-0007" title="CosciaM . Effects of nicergoline in peripheral arteriopathies of the lower limbs. Double-blind study. Minerva Cardioangiologica1972;20(9):497-504. ">Coscia 1972</a>; <a href="./references#CD011033-bbs2-0008" title="HeD . The application of Simiaoyongantangjiawei in the treatment of thromboangiitis obliterans. Chinese Journal of Information on Traditional Chinese Medicine2007;14:76. ">He 2007</a>; <a href="./references#CD011033-bbs2-0009" title="HoshinoS , NakashimaM , KuboY , YasudaK , AbeT , OuchiH , et al. Results of dose finding study of Pamicogrel (KBT-3022) on chronic arterial occlusive diseases. Rinsho Iyaku1997;13:3409-36. ">Hoshino 1997</a>; <a href="./references#CD011033-bbs2-0010" title="MusialJ , WilczynskaM , SladekK , CierniewskiCS , NizankowskiR , SzczeklikA . Fibrinolytic activity of prostacyclin and iloprost in patients with peripheral arterial disease. Prostaglandins1986;31(1):61-70. ">Musial 1986</a>; <a href="./references#CD011033-bbs2-0011" title="ReichertN , ShiboletS , Adar R, GafniJ . Controlled trial of propranolol in intermittent claudication. Clinical Pharmacology and Therapeutics1975;17:612-5. ">Reichert 1975</a>; <a href="./references#CD011033-bbs2-0012" title="SteinorthG . Report on the clinical testing of Lamuran (I). Die Medizinische Welt1967;35:2025-32. ">Steinorth 1967</a>; <a href="./references#CD011033-bbs2-0013" title="SunDX , MuDJ , LiXY . Point injection of prostaglandin E1 on Sanyinjiao Acupuncture (SP6) for thromboangiitis obliterans pain in 24 cases. Zhongguo Zhong Xi Yi Jie He Za Zhi [Chinese Journal of Integrated Traditional and Western Medicine]1993;13:10. ">Sun 1993</a>; <a href="./references#CD011033-bbs2-0014" title="YangL , ZhouCH , YaoT . Clinical study of treating thromboangitis obliterans with overlapping thinning chisel therapy. Chinese Journal of Information on TCM2005;12:73-4. ">Yang 2005</a>; <a href="./references#CD011033-bbs2-0015" title="ZelikovskyA , UrcaI , ShaklaiM , VriesA . A clinical trial with pyridinolcarbamate in the treatment of patients with obstructive diseases of the peripheral arteries. Japanese Heart Journal1973;14:12-21. ">Zelikovsky 1973</a>). The reasons for exclusion are described in the <a href="./references#CD011033-sec-0111" title="">Characteristics of excluded studies</a> table. In brief, the main reasons for exclusion were interventions with no pharmacological agents (e.g. acupuncture, sympathectomy; <a href="./references#CD011033-bbs2-0006" title="BozkurtAK , KoksalC , DemirbasMY , ErdoganA , RahmanA , DemirkilicU , et al. A randomized trial of intravenous iloprost (a stable prostacyclin analogue) versus lumbar sympathectomy in the management of Buerger's disease. International Angiology2006;25:162-8. ">Bozkurt 2006</a>; <a href="./references#CD011033-bbs2-0008" title="HeD . The application of Simiaoyongantangjiawei in the treatment of thromboangiitis obliterans. Chinese Journal of Information on Traditional Chinese Medicine2007;14:76. ">He 2007</a>; <a href="./references#CD011033-bbs2-0013" title="SunDX , MuDJ , LiXY . Point injection of prostaglandin E1 on Sanyinjiao Acupuncture (SP6) for thromboangiitis obliterans pain in 24 cases. Zhongguo Zhong Xi Yi Jie He Za Zhi [Chinese Journal of Integrated Traditional and Western Medicine]1993;13:10. ">Sun 1993</a>; <a href="./references#CD011033-bbs2-0014" title="YangL , ZhouCH , YaoT . Clinical study of treating thromboangitis obliterans with overlapping thinning chisel therapy. Chinese Journal of Information on TCM2005;12:73-4. ">Yang 2005</a>), studies without patients with Buerger's disease (<a href="./references#CD011033-bbs2-0012" title="SteinorthG . Report on the clinical testing of Lamuran (I). Die Medizinische Welt1967;35:2025-32. ">Steinorth 1967</a>), non‐randomised (<a href="./references#CD011033-bbs2-0011" title="ReichertN , ShiboletS , Adar R, GafniJ . Controlled trial of propranolol in intermittent claudication. Clinical Pharmacology and Therapeutics1975;17:612-5. ">Reichert 1975</a>), or participants with mixed diagnoses without a separate description of the outcomes for participants with Buerger's disease (<a href="./references#CD011033-bbs2-0007" title="CosciaM . Effects of nicergoline in peripheral arteriopathies of the lower limbs. Double-blind study. Minerva Cardioangiologica1972;20(9):497-504. ">Coscia 1972</a>; <a href="./references#CD011033-bbs2-0015" title="ZelikovskyA , UrcaI , ShaklaiM , VriesA . A clinical trial with pyridinolcarbamate in the treatment of patients with obstructive diseases of the peripheral arteries. Japanese Heart Journal1973;14:12-21. ">Zelikovsky 1973</a>). <a href="./references#CD011033-bbs2-0010" title="MusialJ , WilczynskaM , SladekK , CierniewskiCS , NizankowskiR , SzczeklikA . Fibrinolytic activity of prostacyclin and iloprost in patients with peripheral arterial disease. Prostaglandins1986;31(1):61-70. ">Musial 1986</a> assessed an outcome (fibrinolytic activity) not relevant for the review. <a href="./references#CD011033-bbs2-0009" title="HoshinoS , NakashimaM , KuboY , YasudaK , AbeT , OuchiH , et al. Results of dose finding study of Pamicogrel (KBT-3022) on chronic arterial occlusive diseases. Rinsho Iyaku1997;13:3409-36. ">Hoshino 1997</a> was classed as an ongoing study in the previous version of the review. As we were unable to locate the full text and determine if it was randomised we have now excluded this study. </p> </section> </section> <section id="CD011033-sec-0048"> <h3 class="title">Risk of bias in included studies</h3> <p>See <a href="#CD011033-fig-0002">Figure 2</a> and <a href="#CD011033-fig-0003">Figure 3</a> for a graphical summary of methodological quality for the included studies, based on the 'Risk of bias' domains. </p> <div class="figure" id="CD011033-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD011033-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/image_n/nCD011033-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD011033-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011033-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/image_n/nCD011033-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD011033-sec-0049"> <h4 class="title">Allocation</h4> <p>Four included studies (<a href="./references#CD011033-bbs2-0002" title="EsatoK , YasudaK , AbeT , HoshinoS , IshimaruS , HoriG , et al. Studies on the clinical efficacy and safety of TTC-909 in the treatment of peripheral arterial occlusive disease: a multi-center double-blind comparison with Alprostadil incorporated in lipid microspheres. Rinsho Iyaku1995;11:2111-2. ">Esato 1995</a>; <a href="./references#CD011033-bbs2-0003" title="DiehmC . Multicenter-study on Iloprost in patients with thromboangiitis obliterans (Buerger's disease). Klinische Wochenschrift1989;67:178-9. FiessingerJN , SchaferM . Trial of iloprost versus aspirin treatment for critical limb ischaemia of thromboangiitis obliterans. Lancet1990;335(8689):555-7. ">Fiessinger 1990</a>; <a href="./references#CD011033-bbs2-0004" title="IshitobiK , et al. Therapeutic efficacy of iloprost, a prostacyclin analogue for chronic arterial occlusion: a double-blind comparative study with PGE1. Rinsho to Kenkyu1991;68:1836-50. ">Ishitobi 1991</a>; <a href="./references#CD011033-bbs2-0005" title="VerstraeteM . Oral iloprost in the treatment of thromboangiitis obliterans (Buerger's disease): a double-blind, randomised, placebo-controlled trial. The European TAO Study Group. European Journal of Vascular and Endovascular Surgery1998;15(4):300-7. ">Verstraete 1998</a>), did not describe the method of randomisation and therefore, were classed as unclear risk of bias. Only <a href="./references#CD011033-bbs2-0001" title="BeigiAA , HoghoughiMA , EshaghianA , ZadeAH , MasoudpourH . The role of folic acid on the hyperhomocysteinemia in the Buerger's disease (thromboangiitis obliterans). Journal of Research in Medical Sciences2014;19:1034-7. ">Beigi 2014</a>, after contact with study authors, was classed as low risk of bias because the trialists used a computerised randomisation method. </p> <p>Allocation concealment was only reported in the <a href="./references#CD011033-bbs2-0003" title="DiehmC . Multicenter-study on Iloprost in patients with thromboangiitis obliterans (Buerger's disease). Klinische Wochenschrift1989;67:178-9. FiessingerJN , SchaferM . Trial of iloprost versus aspirin treatment for critical limb ischaemia of thromboangiitis obliterans. Lancet1990;335(8689):555-7. ">Fiessinger 1990</a> study, which reported the utilization of a centre of randomisation. <a href="./references#CD011033-bbs2-0001" title="BeigiAA , HoghoughiMA , EshaghianA , ZadeAH , MasoudpourH . The role of folic acid on the hyperhomocysteinemia in the Buerger's disease (thromboangiitis obliterans). Journal of Research in Medical Sciences2014;19:1034-7. ">Beigi 2014</a>, after contact with study authors, described a method of allocation concealment based on computerised codes that were in the possession of a third person (not involved in drug administration or outcome assessment). The remaining three studies (<a href="./references#CD011033-bbs2-0002" title="EsatoK , YasudaK , AbeT , HoshinoS , IshimaruS , HoriG , et al. Studies on the clinical efficacy and safety of TTC-909 in the treatment of peripheral arterial occlusive disease: a multi-center double-blind comparison with Alprostadil incorporated in lipid microspheres. Rinsho Iyaku1995;11:2111-2. ">Esato 1995</a>; <a href="./references#CD011033-bbs2-0004" title="IshitobiK , et al. Therapeutic efficacy of iloprost, a prostacyclin analogue for chronic arterial occlusion: a double-blind comparative study with PGE1. Rinsho to Kenkyu1991;68:1836-50. ">Ishitobi 1991</a>; <a href="./references#CD011033-bbs2-0005" title="VerstraeteM . Oral iloprost in the treatment of thromboangiitis obliterans (Buerger's disease): a double-blind, randomised, placebo-controlled trial. The European TAO Study Group. European Journal of Vascular and Endovascular Surgery1998;15(4):300-7. ">Verstraete 1998</a>) were classified as unclear risk of bias. </p> </section> <section id="CD011033-sec-0050"> <h4 class="title">Blinding</h4> <p>All five included studies were blinded for performance bias. <a href="./references#CD011033-bbs2-0001" title="BeigiAA , HoghoughiMA , EshaghianA , ZadeAH , MasoudpourH . The role of folic acid on the hyperhomocysteinemia in the Buerger's disease (thromboangiitis obliterans). Journal of Research in Medical Sciences2014;19:1034-7. ">Beigi 2014</a>, <a href="./references#CD011033-bbs2-0002" title="EsatoK , YasudaK , AbeT , HoshinoS , IshimaruS , HoriG , et al. Studies on the clinical efficacy and safety of TTC-909 in the treatment of peripheral arterial occlusive disease: a multi-center double-blind comparison with Alprostadil incorporated in lipid microspheres. Rinsho Iyaku1995;11:2111-2. ">Esato 1995</a> and <a href="./references#CD011033-bbs2-0003" title="DiehmC . Multicenter-study on Iloprost in patients with thromboangiitis obliterans (Buerger's disease). Klinische Wochenschrift1989;67:178-9. FiessingerJN , SchaferM . Trial of iloprost versus aspirin treatment for critical limb ischaemia of thromboangiitis obliterans. Lancet1990;335(8689):555-7. ">Fiessinger 1990</a> were blinded for detection bias; however, <a href="./references#CD011033-bbs2-0004" title="IshitobiK , et al. Therapeutic efficacy of iloprost, a prostacyclin analogue for chronic arterial occlusion: a double-blind comparative study with PGE1. Rinsho to Kenkyu1991;68:1836-50. ">Ishitobi 1991</a> and <a href="./references#CD011033-bbs2-0005" title="VerstraeteM . Oral iloprost in the treatment of thromboangiitis obliterans (Buerger's disease): a double-blind, randomised, placebo-controlled trial. The European TAO Study Group. European Journal of Vascular and Endovascular Surgery1998;15(4):300-7. ">Verstraete 1998</a> did not report whether the outcome evaluators were blinded and so were at unclear risk of detection bias. </p> </section> <section id="CD011033-sec-0051"> <h4 class="title">Incomplete outcome data</h4> <p><a href="./references#CD011033-bbs2-0001" title="BeigiAA , HoghoughiMA , EshaghianA , ZadeAH , MasoudpourH . The role of folic acid on the hyperhomocysteinemia in the Buerger's disease (thromboangiitis obliterans). Journal of Research in Medical Sciences2014;19:1034-7. ">Beigi 2014</a> described a study without losses to follow‐up. Follow‐up was available to six months and so were at low risk of attrition bias. </p> <p><a href="./references#CD011033-bbs2-0002" title="EsatoK , YasudaK , AbeT , HoshinoS , IshimaruS , HoriG , et al. Studies on the clinical efficacy and safety of TTC-909 in the treatment of peripheral arterial occlusive disease: a multi-center double-blind comparison with Alprostadil incorporated in lipid microspheres. Rinsho Iyaku1995;11:2111-2. ">Esato 1995</a> reported they used intention‐to‐treat analyses, but in practice, adopted 'as‐treated' (per protocol) analyses. All exclusions were explained. Follow‐up was available to four weeks. We judged this study to be at high risk of attrition bias. </p> <p><a href="./references#CD011033-bbs2-0003" title="DiehmC . Multicenter-study on Iloprost in patients with thromboangiitis obliterans (Buerger's disease). Klinische Wochenschrift1989;67:178-9. FiessingerJN , SchaferM . Trial of iloprost versus aspirin treatment for critical limb ischaemia of thromboangiitis obliterans. Lancet1990;335(8689):555-7. ">Fiessinger 1990</a> reported by intention‐to‐treat, and justified all the post‐randomisation exclusions. Follow‐up was available to six months. <a href="./references#CD011033-bbs2-0003" title="DiehmC . Multicenter-study on Iloprost in patients with thromboangiitis obliterans (Buerger's disease). Klinische Wochenschrift1989;67:178-9. FiessingerJN , SchaferM . Trial of iloprost versus aspirin treatment for critical limb ischaemia of thromboangiitis obliterans. Lancet1990;335(8689):555-7. ">Fiessinger 1990</a> was therefore judged to be at low risk of attrition bias. </p> <p>In <a href="./references#CD011033-bbs2-0004" title="IshitobiK , et al. Therapeutic efficacy of iloprost, a prostacyclin analogue for chronic arterial occlusion: a double-blind comparative study with PGE1. Rinsho to Kenkyu1991;68:1836-50. ">Ishitobi 1991</a>, the authors did not clearly describe the losses to follow‐up, declaring only that there were more losses in the iloprost group, but not reporting how many participants and possible reasons. Follow‐up was available to four weeks. <a href="./references#CD011033-bbs2-0004" title="IshitobiK , et al. Therapeutic efficacy of iloprost, a prostacyclin analogue for chronic arterial occlusion: a double-blind comparative study with PGE1. Rinsho to Kenkyu1991;68:1836-50. ">Ishitobi 1991</a> was judged to be of high risk of attrition bias. </p> <p><a href="./references#CD011033-bbs2-0005" title="VerstraeteM . Oral iloprost in the treatment of thromboangiitis obliterans (Buerger's disease): a double-blind, randomised, placebo-controlled trial. The European TAO Study Group. European Journal of Vascular and Endovascular Surgery1998;15(4):300-7. ">Verstraete 1998</a> also reported by intention‐to‐treat, and justified all the post randomisation exclusions. Follow‐up was available to six months. Therefore, <a href="./references#CD011033-bbs2-0005" title="VerstraeteM . Oral iloprost in the treatment of thromboangiitis obliterans (Buerger's disease): a double-blind, randomised, placebo-controlled trial. The European TAO Study Group. European Journal of Vascular and Endovascular Surgery1998;15(4):300-7. ">Verstraete 1998</a> was judged to be at low risk of attrition bias. </p> </section> <section id="CD011033-sec-0052"> <h4 class="title">Selective reporting</h4> <p><a href="./references#CD011033-bbs2-0002" title="EsatoK , YasudaK , AbeT , HoshinoS , IshimaruS , HoriG , et al. Studies on the clinical efficacy and safety of TTC-909 in the treatment of peripheral arterial occlusive disease: a multi-center double-blind comparison with Alprostadil incorporated in lipid microspheres. Rinsho Iyaku1995;11:2111-2. ">Esato 1995</a>, I<a href="./references#CD011033-bbs2-0004" title="IshitobiK , et al. Therapeutic efficacy of iloprost, a prostacyclin analogue for chronic arterial occlusion: a double-blind comparative study with PGE1. Rinsho to Kenkyu1991;68:1836-50. ">shitobi 1991</a>, and <a href="./references#CD011033-bbs2-0005" title="VerstraeteM . Oral iloprost in the treatment of thromboangiitis obliterans (Buerger's disease): a double-blind, randomised, placebo-controlled trial. The European TAO Study Group. European Journal of Vascular and Endovascular Surgery1998;15(4):300-7. ">Verstraete 1998</a> described all outcomes and were judged to be at low risk of reporting bias. <a href="./references#CD011033-bbs2-0001" title="BeigiAA , HoghoughiMA , EshaghianA , ZadeAH , MasoudpourH . The role of folic acid on the hyperhomocysteinemia in the Buerger's disease (thromboangiitis obliterans). Journal of Research in Medical Sciences2014;19:1034-7. ">Beigi 2014</a> did not describe the presence of rest pain or ischaemic ulcers and was judged to be at high risk of reporting bias. In <a href="./references#CD011033-bbs2-0003" title="DiehmC . Multicenter-study on Iloprost in patients with thromboangiitis obliterans (Buerger's disease). Klinische Wochenschrift1989;67:178-9. FiessingerJN , SchaferM . Trial of iloprost versus aspirin treatment for critical limb ischaemia of thromboangiitis obliterans. Lancet1990;335(8689):555-7. ">Fiessinger 1990</a>, there was conflicting data about the number of patients with ulcers healed after treatment (day 28), and uncertain data about number of patients with ulcers healed after six months of follow up. We judged this study to be at unclear risk of reporting bias. </p> </section> <section id="CD011033-sec-0053"> <h4 class="title">Other potential sources of bias</h4> <p>In <a href="./references#CD011033-bbs2-0002" title="EsatoK , YasudaK , AbeT , HoshinoS , IshimaruS , HoriG , et al. Studies on the clinical efficacy and safety of TTC-909 in the treatment of peripheral arterial occlusive disease: a multi-center double-blind comparison with Alprostadil incorporated in lipid microspheres. Rinsho Iyaku1995;11:2111-2. ">Esato 1995</a> and <a href="./references#CD011033-bbs2-0004" title="IshitobiK , et al. Therapeutic efficacy of iloprost, a prostacyclin analogue for chronic arterial occlusion: a double-blind comparative study with PGE1. Rinsho to Kenkyu1991;68:1836-50. ">Ishitobi 1991</a>, the study authors did not describe tobacco exposure before and after the treatment and both were judged to be at high risk of other bias. <a href="./references#CD011033-bbs2-0001" title="BeigiAA , HoghoughiMA , EshaghianA , ZadeAH , MasoudpourH . The role of folic acid on the hyperhomocysteinemia in the Buerger's disease (thromboangiitis obliterans). Journal of Research in Medical Sciences2014;19:1034-7. ">Beigi 2014</a> was judged to be at high risk of other bias because participants without critical ischaemia were eligible, resulting in low chances to be amputated. <a href="./references#CD011033-bbs2-0005" title="VerstraeteM . Oral iloprost in the treatment of thromboangiitis obliterans (Buerger's disease): a double-blind, randomised, placebo-controlled trial. The European TAO Study Group. European Journal of Vascular and Endovascular Surgery1998;15(4):300-7. ">Verstraete 1998</a> was judged to be at unclear risk of bias because there was no information about any potential conflict of interest. <a href="./references#CD011033-bbs2-0003" title="DiehmC . Multicenter-study on Iloprost in patients with thromboangiitis obliterans (Buerger's disease). Klinische Wochenschrift1989;67:178-9. FiessingerJN , SchaferM . Trial of iloprost versus aspirin treatment for critical limb ischaemia of thromboangiitis obliterans. Lancet1990;335(8689):555-7. ">Fiessinger 1990</a> was judged to be at low risk of bias because the proportion of smokers and non‐smokers in the study arms at the beginning and after treatment were described. </p> </section> </section> <section id="CD011033-sec-0054"> <h3 class="title" id="CD011033-sec-0054">Effects of interventions</h3> <p>See: <a href="./full#CD011033-tbl-0001"><b>Summary of findings 1</b> (Oral or intravenous) prostanoid versus aspirin treatment for Buerger's disease</a>; <a href="./full#CD011033-tbl-0002"><b>Summary of findings 2</b> Intravenous prostacyclin analogue versus intravenous prostaglandin analogue for treatment of Buerger's disease</a>; <a href="./full#CD011033-tbl-0003"><b>Summary of findings 3</b> (Oral or intravenous) prostanoid versus placebo for treatment of Buerger's disease</a>; <a href="./full#CD011033-tbl-0004"><b>Summary of findings 4</b> Any pharmacological agent versus placebo or any other pharmacological agent for treatment of Buerger's disease</a> </p> <section id="CD011033-sec-0055"> <h4 class="title">(Oral or intravenous) prostanoid (e.g. iloprost) versus aspirin</h4> <section id="CD011033-sec-0056"> <h5 class="title">Intravenous prostacyclin analogue (iloprost) versus oral aspirin</h5> <p>One study assessed this comparison (<a href="./references#CD011033-bbs2-0003" title="DiehmC . Multicenter-study on Iloprost in patients with thromboangiitis obliterans (Buerger's disease). Klinische Wochenschrift1989;67:178-9. FiessingerJN , SchaferM . Trial of iloprost versus aspirin treatment for critical limb ischaemia of thromboangiitis obliterans. Lancet1990;335(8689):555-7. ">Fiessinger 1990</a>). </p> <section id="CD011033-sec-0057"> <h6 class="title">Ulcer healing</h6> <p>Ulcer healing was assessed at the end of treatment (day 28) and six months after the start of treatment. Complete healing of all ulcers, assessed by an independent evaluator, in the iloprost group was 35% (18/52 patients) compared to 13% (6/46 patients) in the aspirin group at day 28 (RR 2.65; 95% CI 1.15 to 6.11; P = 0.02; moderate‐certainty evidence; <a href="./references#CD011033-fig-0004" title="">Analysis 1.1</a>). We are unclear over the percentage of people who were followed up to six months who had ulcers. It is possible that of the people followed up at six months, some did not have ulcers. The authors describe the results as follows: "14 of 18 patients who achieved complete healing of trophic changes on iloprost treatment were observed at six months, 13 of whom were still completely healed. Three of the five patients who achieved complete healing of trophic changes on aspirin treatment were observed at six months, and were still completely healed". </p> </section> <section id="CD011033-sec-0058"> <h6 class="title">Pain</h6> <p>Pain was assessed at the end of treatment (day 28). Total relief of rest pain in the iloprost group was 63% (43/68 participants) compared to 28% (18/65 participants) in the aspirin group (RR 2.28; 95% CI 1.48 to 3.52; P = 0.0002; moderate‐certainty evidence; <a href="./references#CD011033-fig-0005" title="">Analysis 1.2</a>). </p> </section> <section id="CD011033-sec-0059"> <h6 class="title">Rate of amputation</h6> <p>Rate of amputation: Six months after the start of treatment, three participants treated with iloprost and eight treated with aspirin required major amputation (RR 0.32; 95% CI 0.09 to 1.15; P = 0.08; moderate‐certainty evidence; <a href="./references#CD011033-fig-0006" title="">Analysis 1.3</a>). </p> </section> <section id="CD011033-sec-0060"> <h6 class="title">Side effects</h6> <p>Side effects including headache, flushing, nausea, and abdominal cramps were more common in participants treated with iloprost, but according to the study authors, no participant in either group had to be withdrawn because of side‐effects. </p> <p>The remaining secondary outcomes of amputation‐free survival, walking distance or pain‐free walking, and ankle brachial index were not assessed by <a href="./references#CD011033-bbs2-0003" title="DiehmC . Multicenter-study on Iloprost in patients with thromboangiitis obliterans (Buerger's disease). Klinische Wochenschrift1989;67:178-9. FiessingerJN , SchaferM . Trial of iloprost versus aspirin treatment for critical limb ischaemia of thromboangiitis obliterans. Lancet1990;335(8689):555-7. ">Fiessinger 1990</a>. </p> </section> </section> </section> <section id="CD011033-sec-0061"> <h4 class="title">Intravenous prostacyclin analogue versus intravenous prostaglandin analogue</h4> <p>Two studies assessed this comparison (<a href="./references#CD011033-bbs2-0002" title="EsatoK , YasudaK , AbeT , HoshinoS , IshimaruS , HoriG , et al. Studies on the clinical efficacy and safety of TTC-909 in the treatment of peripheral arterial occlusive disease: a multi-center double-blind comparison with Alprostadil incorporated in lipid microspheres. Rinsho Iyaku1995;11:2111-2. ">Esato 1995</a>; <a href="./references#CD011033-bbs2-0004" title="IshitobiK , et al. Therapeutic efficacy of iloprost, a prostacyclin analogue for chronic arterial occlusion: a double-blind comparative study with PGE1. Rinsho to Kenkyu1991;68:1836-50. ">Ishitobi 1991</a>). <a href="./references#CD011033-bbs2-0002" title="EsatoK , YasudaK , AbeT , HoshinoS , IshimaruS , HoriG , et al. Studies on the clinical efficacy and safety of TTC-909 in the treatment of peripheral arterial occlusive disease: a multi-center double-blind comparison with Alprostadil incorporated in lipid microspheres. Rinsho Iyaku1995;11:2111-2. ">Esato 1995</a> compared intravenous prostacyclin analogue clinprost to intravenous prostaglandin analogue alprostadil. <a href="./references#CD011033-bbs2-0004" title="IshitobiK , et al. Therapeutic efficacy of iloprost, a prostacyclin analogue for chronic arterial occlusion: a double-blind comparative study with PGE1. Rinsho to Kenkyu1991;68:1836-50. ">Ishitobi 1991</a> compared intravenous prostacyclin analogue iloprost to intravenous prostaglandin analogue alprostadil. </p> <section id="CD011033-sec-0062"> <h5 class="title">Ulcer healing</h5> <p><a href="./references#CD011033-bbs2-0002" title="EsatoK , YasudaK , AbeT , HoshinoS , IshimaruS , HoriG , et al. Studies on the clinical efficacy and safety of TTC-909 in the treatment of peripheral arterial occlusive disease: a multi-center double-blind comparison with Alprostadil incorporated in lipid microspheres. Rinsho Iyaku1995;11:2111-2. ">Esato 1995</a> assessed ulcer healing at the end of treatment (4 weeks). Ulcer healing was evaluated by an assistant doctor (a medical researcher responsible for recruiting and outcome evaluation) using metric parameters (ulcer size), presence of granulation tissue and infection status. Improvement of ischaemic ulcers were seen in 70.6% (12/17 participants) in the clinprost group compared to 56.5% (13/23) in the alprostadil group (RR 1.25, 95% of CI 0.78 to 2.00; P = 0.36). Total recuperation was seen in 23.5% (4/17 patients) in the clinprost group compared to 8.7% (2/23 participants) in the alprostadil group (RR 2.38, 95% of CI 0.48 to 11.7). </p> <p><a href="./references#CD011033-bbs2-0004" title="IshitobiK , et al. Therapeutic efficacy of iloprost, a prostacyclin analogue for chronic arterial occlusion: a double-blind comparative study with PGE1. Rinsho to Kenkyu1991;68:1836-50. ">Ishitobi 1991</a> assessed ulcer healing at the end of treatment (day 28). Ulcer healing was assessed by an assistant doctor and was evaluated with metric parameters (ulcer size), presence of granulation tissue, and presence or absence of infection. Posteriorly classified as ulcer healing improvement in Buerger's subgroups, the iloprost group reported 41% (9/22 patients) compared to 41% (11/27) in the alprostadil group (RR 1.00, 95% CI 0.51 to 1.98). </p> <p>Ulcer healing data (improvement of ischaemic ulcers) from <a href="./references#CD011033-bbs2-0002" title="EsatoK , YasudaK , AbeT , HoshinoS , IshimaruS , HoriG , et al. Studies on the clinical efficacy and safety of TTC-909 in the treatment of peripheral arterial occlusive disease: a multi-center double-blind comparison with Alprostadil incorporated in lipid microspheres. Rinsho Iyaku1995;11:2111-2. ">Esato 1995</a> and <a href="./references#CD011033-bbs2-0004" title="IshitobiK , et al. Therapeutic efficacy of iloprost, a prostacyclin analogue for chronic arterial occlusion: a double-blind comparative study with PGE1. Rinsho to Kenkyu1991;68:1836-50. ">Ishitobi 1991</a> were pooled and showed no clear difference between the treatment groups (RR 1.13, 95% CI 0.76 to 1.69; 89 participants; 2 studies; P = 0.54; I² = 0%; very low‐certainty evidence; <a href="./references#CD011033-fig-0007" title="">Analysis 2.1</a>; <a href="./references#CD011033-bbs2-0002" title="EsatoK , YasudaK , AbeT , HoshinoS , IshimaruS , HoriG , et al. Studies on the clinical efficacy and safety of TTC-909 in the treatment of peripheral arterial occlusive disease: a multi-center double-blind comparison with Alprostadil incorporated in lipid microspheres. Rinsho Iyaku1995;11:2111-2. ">Esato 1995</a>; <a href="./references#CD011033-bbs2-0004" title="IshitobiK , et al. Therapeutic efficacy of iloprost, a prostacyclin analogue for chronic arterial occlusion: a double-blind comparative study with PGE1. Rinsho to Kenkyu1991;68:1836-50. ">Ishitobi 1991</a>). </p> </section> <section id="CD011033-sec-0063"> <h5 class="title">Pain</h5> <p><a href="./references#CD011033-bbs2-0002" title="EsatoK , YasudaK , AbeT , HoshinoS , IshimaruS , HoriG , et al. Studies on the clinical efficacy and safety of TTC-909 in the treatment of peripheral arterial occlusive disease: a multi-center double-blind comparison with Alprostadil incorporated in lipid microspheres. Rinsho Iyaku1995;11:2111-2. ">Esato 1995</a> assessed pain at the end of treatment (four weeks). Pain was evaluated by an assistant doctor. Fifty percent (8/16 participants) of the clinprost group were free of pain compared with 31.8% of the alprostadil group (7/22 patients; RR 1.57; 95% CI 0.72 to 3.44; P = 0.26; low‐certainty evidence; <a href="./references#CD011033-fig-0008" title="">Analysis 2.2</a>). </p> <p>In <a href="./references#CD011033-bbs2-0004" title="IshitobiK , et al. Therapeutic efficacy of iloprost, a prostacyclin analogue for chronic arterial occlusion: a double-blind comparative study with PGE1. Rinsho to Kenkyu1991;68:1836-50. ">Ishitobi 1991</a>, pain was not measured with a validated score or scale, or a quality of life questionnaire. Pain was assessed using five levels (1 = much better, 2 = better, 3 = little better, 4 = no difference, and 5 = worse). Participants in the iloprost group reported pain as: much better = 21.7% (5/23 patients), better = 34.8% (8/23 patients), little better = 17.4% (4/23 patients), no difference = 21.7% (5/23 patients), and worse = 4.4% (1/23 patients). Participants in the alprostadil group reported pain as: much better = 28.5% (8/28 patients), better = 32.1% (9/28 patients), little better = 14.3 % (4/28 patients), no difference = 21.5% (6/28 patients), and worse = 3.6% (1/28 patients). <a href="./references#CD011033-bbs2-0004" title="IshitobiK , et al. Therapeutic efficacy of iloprost, a prostacyclin analogue for chronic arterial occlusion: a double-blind comparative study with PGE1. Rinsho to Kenkyu1991;68:1836-50. ">Ishitobi 1991</a> reported that this finding was not statistically significant. </p> </section> <section id="CD011033-sec-0064"> <h5 class="title">Rate of amputation</h5> <p>Rate of amputation was not appraised by <a href="./references#CD011033-bbs2-0002" title="EsatoK , YasudaK , AbeT , HoshinoS , IshimaruS , HoriG , et al. Studies on the clinical efficacy and safety of TTC-909 in the treatment of peripheral arterial occlusive disease: a multi-center double-blind comparison with Alprostadil incorporated in lipid microspheres. Rinsho Iyaku1995;11:2111-2. ">Esato 1995</a> or <a href="./references#CD011033-bbs2-0004" title="IshitobiK , et al. Therapeutic efficacy of iloprost, a prostacyclin analogue for chronic arterial occlusion: a double-blind comparative study with PGE1. Rinsho to Kenkyu1991;68:1836-50. ">Ishitobi 1991</a>. </p> </section> <section id="CD011033-sec-0065"> <h5 class="title">Side effects</h5> <p><a href="./references#CD011033-bbs2-0002" title="EsatoK , YasudaK , AbeT , HoshinoS , IshimaruS , HoriG , et al. Studies on the clinical efficacy and safety of TTC-909 in the treatment of peripheral arterial occlusive disease: a multi-center double-blind comparison with Alprostadil incorporated in lipid microspheres. Rinsho Iyaku1995;11:2111-2. ">Esato 1995</a> reported that five participants in the clinprost group and two participants in the alprostadil group experienced side effects. In the clinprost group, one participant developed nausea, tinnitus and vertigo in the third week of drug administration, without serious repercussion; another three participants had modification of blood tests relating to liver function, but without further repercussions after the drug administration was ceased, and one participant developed limb edema, probably not related to the clinprost use. The alprostadil group had one participant with modification in blood tests relating to liver function, but also without further repercussions after the drug administration was ceased, and another participant experienced a heat sensation in the head, only on the first day of treatment. </p> <p>Side effects were not clearly specified in <a href="./references#CD011033-bbs2-0004" title="IshitobiK , et al. Therapeutic efficacy of iloprost, a prostacyclin analogue for chronic arterial occlusion: a double-blind comparative study with PGE1. Rinsho to Kenkyu1991;68:1836-50. ">Ishitobi 1991</a> for patients with Buerger's disease. Overall, 13 participants (17.3%) in the iloprost group and 11 participants (13.9%) in the alprostadil group experienced side effects, such as headache, vomiting, and flushing. </p> <p>The remaining secondary outcomes of amputation‐free survival, walking distance or pain‐free walking, and ankle brachial index were not appraised by <a href="./references#CD011033-bbs2-0002" title="EsatoK , YasudaK , AbeT , HoshinoS , IshimaruS , HoriG , et al. Studies on the clinical efficacy and safety of TTC-909 in the treatment of peripheral arterial occlusive disease: a multi-center double-blind comparison with Alprostadil incorporated in lipid microspheres. Rinsho Iyaku1995;11:2111-2. ">Esato 1995</a> or <a href="./references#CD011033-bbs2-0004" title="IshitobiK , et al. Therapeutic efficacy of iloprost, a prostacyclin analogue for chronic arterial occlusion: a double-blind comparative study with PGE1. Rinsho to Kenkyu1991;68:1836-50. ">Ishitobi 1991</a>. </p> </section> </section> <section id="CD011033-sec-0066"> <h4 class="title">(Oral or intravenous) prostanoid versus placebo</h4> <section id="CD011033-sec-0067"> <h5 class="title">Oral prostacyclin analogue (iloprost) versus placebo</h5> <p>One study assessed this comparison (<a href="./references#CD011033-bbs2-0005" title="VerstraeteM . Oral iloprost in the treatment of thromboangiitis obliterans (Buerger's disease): a double-blind, randomised, placebo-controlled trial. The European TAO Study Group. European Journal of Vascular and Endovascular Surgery1998;15(4):300-7. ">Verstraete 1998</a>). </p> <section id="CD011033-sec-0068"> <h6 class="title">Ulcer healing</h6> <p>Ulcer healing was assessed at the end of treatment (eight weeks) and six months after the start of treatment. After eight weeks (end of treatment), complete healing of all ulcers was 19% in the 200 mcg iloprost group (12/63 participants; RR 1.11; 95% CI 0.54 to 2.29; P = 0.78; moderate‐certainty evidence), 15% in the 400 mcg iloprost group (10/65 participants; RR 0.90; 95% CI 0.42 to 1.93; P = 0.78; moderate‐certainty evidence), and 17% in the placebo group (12/70 participants; <a href="./references#CD011033-fig-0009" title="">Analysis 3.1</a>; <a href="./references#CD011033-fig-0010" title="">Analysis 3.2</a>). After six months, the 200 mcg iloprost group reported complete healing of all ulcers in 49% (31/63 participants; RR 1.19; 95% CI 0.82 to 1.73; P = 0.37; moderate‐certainty evidence), the 400 mcg iloprost group reported 41% (27/65 participants; RR 1.00; 95% CI 0.67 to 1.50; P = 0.99; moderate‐certainty evidence), and the placebo group reported 41% (29/70 participants) complete healing of all ulcers (<a href="./references#CD011033-fig-0011" title="">Analysis 3.3</a>; <a href="./references#CD011033-fig-0012" title="">Analysis 3.4</a>). </p> <p><a href="./references#CD011033-bbs2-0005" title="VerstraeteM . Oral iloprost in the treatment of thromboangiitis obliterans (Buerger's disease): a double-blind, randomised, placebo-controlled trial. The European TAO Study Group. European Journal of Vascular and Endovascular Surgery1998;15(4):300-7. ">Verstraete 1998</a> also reported improvement of the most important ulcer (improved healing was not a defined outcome in this review): improvement of the most important ulcer was 55% in the 200 mcg iloprost group (P = 0.056 versus placebo), 63% in the 400 mcg iloprost group (P = 0.008 versus placebo), and 40% in the placebo group after eight weeks (end of treatment). After six months, the 200 mcg iloprost group reported improvement of the most important ulcer in 84% (P = 0.007 versus placebo), the 400 mcg iloprost group reported improvement in 68% (P = 0.297 versus placebo), and the placebo group reported improvement in 62%. </p> </section> <section id="CD011033-sec-0069"> <h6 class="title">Pain</h6> <p>Pain was assessed at the end of treatment (eight weeks) and six months after the start of treatment. After eight weeks (end of treatment), complete relief of rest pain was 39% in the 200 mcg iloprost group (41/105 participants; RR 1.14; 95% CI 0.79 to 1.63; P = 0.48; moderate‐certainty evidence), 38% in the 400 mcg iloprost group (41/108 participants; RR 1.11; 95% CI 0.77 to 1.59; P = 0.58, moderate‐certainty evidence), and 34% in the placebo group (35/102 participants; <a href="./references#CD011033-fig-0013" title="">Analysis 3.5</a>; <a href="./references#CD011033-fig-0014" title="">Analysis 3.6</a>). After six months, the 200 mcg iloprost group reported complete relief of rest pain in 63% (66/105 participants; RR 1.28; 95% CI 1.00 to 1.64; P = 0.05; low‐certainty evidence), the 400 mcg iloprost group reported 49% (53/108 participants; RR 1.00; 95% CI 0.76 to 1.32; P = 0.99; moderate‐certainty evidence), and the placebo group reported 49% (50/102 participants) complete relief of rest pain (<a href="./references#CD011033-fig-0015" title="">Analysis 3.7</a>; <a href="./references#CD011033-fig-0016" title="">Analysis 3.8</a>). </p> </section> <section id="CD011033-sec-0070"> <h6 class="title">Rate of amputation</h6> <p>Rate of amputation was assessed at six months after the start of treatment: the placebo group reported 9% major amputations (9/103 participants), the 200 mcg iloprost group reported 4.7% major amputations (5/106 participants; RR 0.54; 95% CI 0.19 to 1.56; P = 0.25; moderate‐certainty evidence; <a href="./references#CD011033-fig-0017" title="">Analysis 3.9</a>), and the 400 mcg iloprost group reported 3.6% major amputations (4/110 participants; RR 0.42; 95% CI 0.13 to 1.31; P = 0.13; moderate‐certainty evidence; <a href="./references#CD011033-fig-0018" title="">Analysis 3.10</a>). </p> </section> <section id="CD011033-sec-0071"> <h6 class="title">Side effects</h6> <p>Participants in the 400 mcg iloprost group developed about 25% more (68%) side effects than participants in the 200 mcg iloprost group (43%) and the placebo group (38%). According to the study authors, the most frequent side effect reported was headache (more than 20%), followed by vasodilatation and trismus (the latter two cases for the high‐dose iloprost group only). </p> <p>The remaining secondary outcomes of amputation‐free survival, walking distance or pain‐free walking, and ankle brachial index were not assessed by <a href="./references#CD011033-bbs2-0005" title="VerstraeteM . Oral iloprost in the treatment of thromboangiitis obliterans (Buerger's disease): a double-blind, randomised, placebo-controlled trial. The European TAO Study Group. European Journal of Vascular and Endovascular Surgery1998;15(4):300-7. ">Verstraete 1998</a>. </p> </section> </section> </section> <section id="CD011033-sec-0072"> <h4 class="title">Any pharmacological agent versus placebo or any other pharmacological agent</h4> <section id="CD011033-sec-0073"> <h5 class="title">Folic acid versus placebo</h5> <p>One study assessed this comparison (<a href="./references#CD011033-bbs2-0001" title="BeigiAA , HoghoughiMA , EshaghianA , ZadeAH , MasoudpourH . The role of folic acid on the hyperhomocysteinemia in the Buerger's disease (thromboangiitis obliterans). Journal of Research in Medical Sciences2014;19:1034-7. ">Beigi 2014</a>). </p> <section id="CD011033-sec-0074"> <h6 class="title">Ulcer healing</h6> <p>Ulcer healing was not evaluated by <a href="./references#CD011033-bbs2-0001" title="BeigiAA , HoghoughiMA , EshaghianA , ZadeAH , MasoudpourH . The role of folic acid on the hyperhomocysteinemia in the Buerger's disease (thromboangiitis obliterans). Journal of Research in Medical Sciences2014;19:1034-7. ">Beigi 2014</a>. </p> </section> <section id="CD011033-sec-0075"> <h6 class="title">Pain assessment</h6> <p>Pain was assessed at baseline, two months and six months, using a Visual Analogue Scale (VAS), a continuous scale, ranging from 0 to 10, where a higher score means more pain. At baseline, the mean VAS score in the folic acid group was 7.07 points (SD 2.82), and the placebo group was 5.9 points (SD 2.21), resulting in MD 1.17; CI ‐0.66 to 3.00; P = 0.21; very low‐certainty evidence. At two months, the folic acid group was 5.45 points (SD 2.75), and the placebo group was 5.75 points (SD 1.99) resulting in MD ‐0.30; CI ‐2.04 to 1.44; P = 0.74, very low‐certainty evidence. After six months, the folic acid group was 3.46 points (SD 2.57), and the placebo group was 4.82 points (SD 2.46), resulting in MD ‐1.36; CI ‐3.17 to 0.45; P = 0.14, very low‐certainty evidence. (<a href="./references#CD011033-fig-0019" title="">Analysis 4.1</a>; <a href="./references#CD011033-fig-0020" title="">Analysis 4.2</a>; <a href="./references#CD011033-fig-0021" title="">Analysis 4.3</a>). </p> </section> <section id="CD011033-sec-0076"> <h6 class="title">Rate of amputation</h6> <p>Rate of amputation was assessed at baseline, two months, and six months after the beginning of treatment. At baseline, five participants (5/14) in the folic acid group and four participants (4/16) in the placebo group had minor amputations; one participant (1/14) in the folic acid group and none of the participants in the placebo group had a major amputation. There was no change in the number of participants with amputations during the entire study; that is, at two months and six months, no new cases of major or minor amputation were observed very low‐certainty evidence. According to the study authors, the differences between the folic acid and placebo groups were not statistically significant (<a href="./references#CD011033-fig-0022" title="">Analysis 4.4</a>; <a href="./references#CD011033-fig-0023" title="">Analysis 4.5</a>). </p> </section> <section id="CD011033-sec-0077"> <h6 class="title">Side effects</h6> <p>No side effects were reported.</p> <p>The remaining secondary outcomes of amputation‐free survival, walking distance or pain‐free walking, and ankle brachial index were not assessed by <a href="./references#CD011033-bbs2-0001" title="BeigiAA , HoghoughiMA , EshaghianA , ZadeAH , MasoudpourH . The role of folic acid on the hyperhomocysteinemia in the Buerger's disease (thromboangiitis obliterans). Journal of Research in Medical Sciences2014;19:1034-7. ">Beigi 2014</a>. </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD011033-sec-0078" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD011033-sec-0078"></div> <section id="CD011033-sec-0079"> <h3 class="title" id="CD011033-sec-0079">Summary of main results</h3> <p>The five included studies evaluated 602 participants and appraised the efficacy of prostacyclin or prostaglandin analogues against another drug or placebo, in patients with Buerger's disease. Folic acid was also evaluated against placebo in one more recent study. </p> <p>Prostacyclin analogue iloprost, intravenously administered, was effective in healing ulcers and eradicating rest pain after 28 days of treatment, when compared with aspirin (moderate‐certainty evidence). However, this evidence was restricted to a single study (133 participants), and consequently, the reproducibility of results is questionable. </p> <p>Equivalent efficacy was discovered between prostacyclin (iloprost and clinprost) and prostaglandin (alprostadil) analogues as analysed by two studies, when evaluating ulcer healing (very low‐certainty evidence), and rest pain resolution after 28 days of treatment (low‐certainty evidence). </p> <p>Oral prostacyclin analogue iloprost was not effective in healing ischaemic ulcers (moderate‐certainty evidence), or eradicating rest pain (moderate‐certainty evidence), when measured at the end of treatment and six months later, when compared with placebo. Evidence related to efficacy about rest pain resolution after six months of treatment with iloprost 200 mcg was inconsistent with a dose‐response relationship, and the magnitude of the effect observed was low (RR 1.28; 95% CI 1.00 to 1.64; (low‐certainty evidence); thus, the evidence is questionable. </p> <p>In patients with Buerger's disease and hyperhomocysteinaemia, folic acid, when compared with placebo, did not demonstrate a protective effect against amputations, because there was an absence of amputations in both groups (very low‐certainty evidence). Another outcome presented was pain; results found no clear differences between the groups (very low‐certainty evidence). However, the participants chosen were classed as Fontaine II; in other words, they did not have rest pain. </p> <p>In most cases, treatment side effects experienced by the participants, such as headaches, flushing, or nausea, did not lead to treatment interruptions or more serious consequences. None of the included studies assessed amputation‐free survival, walking distance or pain‐free walking distance, or ankle brachial index. </p> </section> <section id="CD011033-sec-0080"> <h3 class="title" id="CD011033-sec-0080">Overall completeness and applicability of evidence</h3> <p>The main objective of this review was to assess the effectiveness of the pharmacological agents administered in patients with Buerger’s disease at different stages of ischaemia. However, we identified only a small number of studies (five randomised controlled trials) with patients of more severe stages of the disease (ulcers, rest pain, or both). In fact, more severe cases of Buerger’s disease are often treated with therapies for limb ischaemia, such as sympathectomy and pharmacological treatment, rather than limb revascularisation. </p> <p>Interventions in the five studies were limited to evaluating prostaglandin and prostacyclin analogues, and folic acid, and did not evaluate other pharmacological agents such as cilostazol, clopidogrel, and pentoxifylline versus placebo or each other. </p> <p>Another important issue concerns the period of treatment. This was limited to four or eight weeks in the included studies. Perhaps prolonged administration until, for example, complete healing or total relief of rest pain, could improve the success of the treatment. </p> <p>Evidence suggested that iloprost, given intravenously, was more effective than aspirin in healing ischaemic ulcers and eradicating rest pain. This evidence was generated with an interesting comparative i.e. aspirin; patients with severe Buerger’s disease with limited treatment options are often treated as patients with atherosclerotic aetiology. </p> <p>Outcomes measured in the studies were limited to assessments of ulcer healing and pain. Particularly problematic was pain evaluation. No study used a validated pain score or scale, or quality of life questionnaires, and consequently, more detailed assessments of pain was not possible. Amputation free‐survival, walking distance or pain‐free walking, and ankle brachial index were not assessed in any of the included studies. </p> <p>Very‐low certainty evidence suggested that folic acid did not provide a protective effect against amputations and rest pain in patients with Buerger's disease and hyperhomocysteinaemia. Therefore, routine folic acid administration in patients with Buerger's disease and hyperhomocysteinaemia remains questionable. </p> </section> <section id="CD011033-sec-0081"> <h3 class="title" id="CD011033-sec-0081">Quality of the evidence</h3> <p>Overall, the certainty of the evidence was very low to moderate, with few studies, a small number of participants and potential for biases such as randomisation and allocation concealment methods. </p> <p>We have summarised the certainty of the evidence for the main comparisons below:</p> <section id="CD011033-sec-0082"> <h4 class="title">Intravenous prostacyclin analogue iloprost versus oral aspirin</h4> <p>See <a href="./full#CD011033-tbl-0001">summary of findings Table 1</a>. Classified as moderate‐certainty evidence. The evidence was obtained from a randomised controlled trial, with low risk of bias, and showed a large magnitude of effect (RR &gt; 2.0). However, just one study was available for this comparison and additional data about reproducibility of the outcomes were not available, therefore we downgraded by one step due to imprecision. </p> </section> <section id="CD011033-sec-0083"> <h4 class="title">Intravenous prostacyclin analogue versus intravenous prostaglandin analogue</h4> <p>See <a href="./full#CD011033-tbl-0002">summary of findings Table 2</a>. Classified as low and very low‐certainty evidence. The evidence was obtained from two randomised controlled trials, which were double‐blinded and demonstrated low heterogeneity, but the evidence was downgraded because a small number of participants was evaluated, and most importantly, the proportion of tobacco exposure between groups, and before the start of treatment was not described. In addition, 'as‐treated' (per‐protocol) analyses were adopted further downgrading the certainty of evidence for ulcer healing. </p> </section> <section id="CD011033-sec-0084"> <h4 class="title">Oral prostacyclin analogue (iloprost) versus placebo</h4> <p>See <a href="./full#CD011033-tbl-0003">summary of findings Table 3</a>. Classified as moderate and low‐certainty evidence. The evidence was obtained from a randomised controlled trial, with overall low risk of bias. However, just one study was available for this comparison and additional data about reproducibility of the outcomes were not available. In addition, evidence suggesting relief of rest pain was found with low dose of iloprost (200 mcg) but not with high dose of iloprost (400 mcg), demonstrating absence of a dose‐response effect and, consequently, downgrading the certainty of the evidence for relief of rest pain after six months to low. </p> </section> <section id="CD011033-sec-0085"> <h4 class="title">Folic acid versus placebo</h4> <p>See <a href="./full#CD011033-tbl-0004">summary of findings Table 4</a>. Classified as very low‐certainty of evidence. One study with a small number of participants was available for this comparison and additional data about reproducibility of the outcomes were not available. In addition, participants without critical ischaemia were recruited into the trial, resulting in the absence of amputations and no differences in pain score in both groups. </p> </section> </section> <section id="CD011033-sec-0086"> <h3 class="title" id="CD011033-sec-0086">Potential biases in the review process</h3> <p>The study of <a href="./references#CD011033-bbs2-0009" title="HoshinoS , NakashimaM , KuboY , YasudaK , AbeT , OuchiH , et al. Results of dose finding study of Pamicogrel (KBT-3022) on chronic arterial occlusive diseases. Rinsho Iyaku1997;13:3409-36. ">Hoshino 1997</a> which assessed the efficacy of pamicogrel (antiplatelet drug) in patients with Buerger's disease, was not included in this review because a full report was not available. Thus, a potential pharmacological agent was not evaluated. Another potential bias relates to pain assessment. For the evaluation of the treatment effect on pain, we only considered absence or presence of pain in the included studies, because none of the included studies used a validated pain scale or score for appropriate assessment. </p> </section> <section id="CD011033-sec-0087"> <h3 class="title" id="CD011033-sec-0087">Agreements and disagreements with other studies or reviews</h3> <p>We did not identify any other systematic reviews about the pharmacological treatment for Buerger’s disease. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD011033-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/urn:x-wiley:14651858:media:CD011033:CD011033-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD011033-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/image_n/nCD011033-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/image_t/tCD011033-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/full#CD011033-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/image_n/nCD011033-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011033-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/urn:x-wiley:14651858:media:CD011033:CD011033-FIG-02" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD011033-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/image_n/nCD011033-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/image_t/tCD011033-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/full#CD011033-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/image_n/nCD011033-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011033-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/urn:x-wiley:14651858:media:CD011033:CD011033-FIG-03" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011033-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/image_n/nCD011033-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/image_t/tCD011033-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/full#CD011033-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/image_n/nCD011033-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011033-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/urn:x-wiley:14651858:media:CD011033:CD011033-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Intravenous prostacyclin analogue (iloprost) versus oral aspirin, Outcome 1: Ulcer healing (4 weeks)" data-id="CD011033-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/image_n/nCD011033-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/image_t/tCD011033-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Intravenous prostacyclin analogue (iloprost) versus oral aspirin, Outcome 1: Ulcer healing (4 weeks) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/references#CD011033-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/image_n/nCD011033-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011033-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/urn:x-wiley:14651858:media:CD011033:CD011033-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Intravenous prostacyclin analogue (iloprost) versus oral aspirin, Outcome 2: Complete relief of rest pain (4 weeks)" data-id="CD011033-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/image_n/nCD011033-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/image_t/tCD011033-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Intravenous prostacyclin analogue (iloprost) versus oral aspirin, Outcome 2: Complete relief of rest pain (4 weeks) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/references#CD011033-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/image_n/nCD011033-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011033-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/urn:x-wiley:14651858:media:CD011033:CD011033-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Intravenous prostacyclin analogue (iloprost) versus oral aspirin, Outcome 3: Rate of amputation" data-id="CD011033-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/image_n/nCD011033-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/image_t/tCD011033-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Intravenous prostacyclin analogue (iloprost) versus oral aspirin, Outcome 3: Rate of amputation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/references#CD011033-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/image_n/nCD011033-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011033-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/urn:x-wiley:14651858:media:CD011033:CD011033-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Prostacyclin versus prostaglandin E1, Outcome 1: Ulcer healing" data-id="CD011033-fig-0007" src="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/image_n/nCD011033-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/image_t/tCD011033-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Prostacyclin versus prostaglandin E1, Outcome 1: Ulcer healing</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/references#CD011033-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/image_n/nCD011033-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011033-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/urn:x-wiley:14651858:media:CD011033:CD011033-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Prostacyclin versus prostaglandin E1, Outcome 2: Complete relief of pain" data-id="CD011033-fig-0008" src="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/image_n/nCD011033-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/image_t/tCD011033-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Prostacyclin versus prostaglandin E1, Outcome 2: Complete relief of pain </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/references#CD011033-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/image_n/nCD011033-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011033-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/urn:x-wiley:14651858:media:CD011033:CD011033-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Oral prostacyclin analogue (iloprost) versus placebo, Outcome 1: Ulcer healing (8 weeks) ‐ iloprost 200 mcg" data-id="CD011033-fig-0009" src="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/image_n/nCD011033-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/image_t/tCD011033-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Oral prostacyclin analogue (iloprost) versus placebo, Outcome 1: Ulcer healing (8 weeks) ‐ iloprost 200 mcg </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/references#CD011033-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/image_n/nCD011033-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011033-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/urn:x-wiley:14651858:media:CD011033:CD011033-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Oral prostacyclin analogue (iloprost) versus placebo, Outcome 2: Ulcer healing (8 weeks) ‐ iloprost 400 mcg" data-id="CD011033-fig-0010" src="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/image_n/nCD011033-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/image_t/tCD011033-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Oral prostacyclin analogue (iloprost) versus placebo, Outcome 2: Ulcer healing (8 weeks) ‐ iloprost 400 mcg </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/references#CD011033-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/image_n/nCD011033-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011033-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/urn:x-wiley:14651858:media:CD011033:CD011033-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Oral prostacyclin analogue (iloprost) versus placebo, Outcome 3: Ulcer healing (6 months) ‐ iloprost 200 mcg" data-id="CD011033-fig-0011" src="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/image_n/nCD011033-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/image_t/tCD011033-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Oral prostacyclin analogue (iloprost) versus placebo, Outcome 3: Ulcer healing (6 months) ‐ iloprost 200 mcg </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/references#CD011033-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/image_n/nCD011033-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011033-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/urn:x-wiley:14651858:media:CD011033:CD011033-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Oral prostacyclin analogue (iloprost) versus placebo, Outcome 4: Ulcer healing (6 months) ‐ iloprost 400 mcg" data-id="CD011033-fig-0012" src="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/image_n/nCD011033-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/image_t/tCD011033-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Oral prostacyclin analogue (iloprost) versus placebo, Outcome 4: Ulcer healing (6 months) ‐ iloprost 400 mcg </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/references#CD011033-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/image_n/nCD011033-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011033-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/urn:x-wiley:14651858:media:CD011033:CD011033-CMP-003.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Oral prostacyclin analogue (iloprost) versus placebo, Outcome 5: Complete relief of rest pain (8 weeks) ‐ iloprost 200 mcg" data-id="CD011033-fig-0013" src="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/image_n/nCD011033-CMP-003.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/image_t/tCD011033-CMP-003.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3: Oral prostacyclin analogue (iloprost) versus placebo, Outcome 5: Complete relief of rest pain (8 weeks) ‐ iloprost 200 mcg </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/references#CD011033-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/image_n/nCD011033-CMP-003.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011033-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/urn:x-wiley:14651858:media:CD011033:CD011033-CMP-003.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Oral prostacyclin analogue (iloprost) versus placebo, Outcome 6: Complete relief of rest pain (8 weeks) ‐ iloprost 400 mcg" data-id="CD011033-fig-0014" src="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/image_n/nCD011033-CMP-003.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/image_t/tCD011033-CMP-003.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3: Oral prostacyclin analogue (iloprost) versus placebo, Outcome 6: Complete relief of rest pain (8 weeks) ‐ iloprost 400 mcg </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/references#CD011033-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/image_n/nCD011033-CMP-003.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011033-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/urn:x-wiley:14651858:media:CD011033:CD011033-CMP-003.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Oral prostacyclin analogue (iloprost) versus placebo, Outcome 7: Complete relief of rest pain (6 months) ‐ iloprost 200 mcg" data-id="CD011033-fig-0015" src="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/image_n/nCD011033-CMP-003.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/image_t/tCD011033-CMP-003.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3: Oral prostacyclin analogue (iloprost) versus placebo, Outcome 7: Complete relief of rest pain (6 months) ‐ iloprost 200 mcg </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/references#CD011033-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/image_n/nCD011033-CMP-003.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011033-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/urn:x-wiley:14651858:media:CD011033:CD011033-CMP-003.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Oral prostacyclin analogue (iloprost) versus placebo, Outcome 8: Complete relief of rest pain (6 months) ‐ iloprost 400 mcg" data-id="CD011033-fig-0016" src="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/image_n/nCD011033-CMP-003.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/image_t/tCD011033-CMP-003.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3: Oral prostacyclin analogue (iloprost) versus placebo, Outcome 8: Complete relief of rest pain (6 months) ‐ iloprost 400 mcg </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/references#CD011033-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/image_n/nCD011033-CMP-003.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011033-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/urn:x-wiley:14651858:media:CD011033:CD011033-CMP-003.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Oral prostacyclin analogue (iloprost) versus placebo, Outcome 9: Rate of amputation ‐ iloprost 200 mcg" data-id="CD011033-fig-0017" src="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/image_n/nCD011033-CMP-003.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/image_t/tCD011033-CMP-003.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3: Oral prostacyclin analogue (iloprost) versus placebo, Outcome 9: Rate of amputation ‐ iloprost 200 mcg </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/references#CD011033-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/image_n/nCD011033-CMP-003.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011033-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/urn:x-wiley:14651858:media:CD011033:CD011033-CMP-003.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Oral prostacyclin analogue (iloprost) versus placebo, Outcome 10: Rate of amputation ‐ iloprost 400 mcg" data-id="CD011033-fig-0018" src="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/image_n/nCD011033-CMP-003.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/image_t/tCD011033-CMP-003.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.10</div> <div class="figure-caption"> <p>Comparison 3: Oral prostacyclin analogue (iloprost) versus placebo, Outcome 10: Rate of amputation ‐ iloprost 400 mcg </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/references#CD011033-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/image_n/nCD011033-CMP-003.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011033-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/urn:x-wiley:14651858:media:CD011033:CD011033-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Folic acid versus placebo, Outcome 1: Pain (0 month)" data-id="CD011033-fig-0019" src="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/image_n/nCD011033-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/image_t/tCD011033-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Folic acid versus placebo, Outcome 1: Pain (0 month)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/references#CD011033-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/image_n/nCD011033-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011033-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/urn:x-wiley:14651858:media:CD011033:CD011033-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Folic acid versus placebo, Outcome 2: Pain (2 months)" data-id="CD011033-fig-0020" src="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/image_n/nCD011033-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/image_t/tCD011033-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Folic acid versus placebo, Outcome 2: Pain (2 months)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/references#CD011033-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/image_n/nCD011033-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011033-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/urn:x-wiley:14651858:media:CD011033:CD011033-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Folic acid versus placebo, Outcome 3: Pain (6 months)" data-id="CD011033-fig-0021" src="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/image_n/nCD011033-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/image_t/tCD011033-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: Folic acid versus placebo, Outcome 3: Pain (6 months)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/references#CD011033-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/image_n/nCD011033-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011033-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/urn:x-wiley:14651858:media:CD011033:CD011033-CMP-004.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Folic acid versus placebo, Outcome 4: Change in rate of amputation (2 months)" data-id="CD011033-fig-0022" src="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/image_n/nCD011033-CMP-004.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/image_t/tCD011033-CMP-004.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4: Folic acid versus placebo, Outcome 4: Change in rate of amputation (2 months) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/references#CD011033-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/image_n/nCD011033-CMP-004.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011033-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/urn:x-wiley:14651858:media:CD011033:CD011033-CMP-004.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Folic acid versus placebo, Outcome 5: Change in rate of amputation (6 months)" data-id="CD011033-fig-0023" src="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/image_n/nCD011033-CMP-004.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/image_t/tCD011033-CMP-004.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4: Folic acid versus placebo, Outcome 5: Change in rate of amputation (6 months) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/references#CD011033-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/media/CDSR/CD011033/image_n/nCD011033-CMP-004.05.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD011033-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">(Oral or intravenous) prostanoid versus aspirin treatment for Buerger's disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Intravenous prostacyclin analogue (iloprost) versus oral aspirin for treatment of Buerger's disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with Buerger's disease </p> <p><b>Settings:</b> hospital and community </p> <p><b>Intervention:</b> intravenous prostacyclin analogue (iloprost) </p> <p><b>Comparison:</b> oral aspirin </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects * (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with oral aspirin</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with intravenous prostacyclin analogue (iloprost)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Ulcer healing</b> </p> <p>Follow‐up: 28 days</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population (28 days)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 2.65</b> (1.15 to 6.11) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>98<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<sup>1,2</sup><br/><b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>130 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>346 per 1000</b> </p> <p>(150 to 797)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Complete relief of rest pain</b> </p> <p>Follow‐up: 28 days</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 2.28</b> (1.48 to 3.52) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>133<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<sup>1,2</sup><br/><b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>277 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>631 per 1000</b> </p> <p>(410 to 975)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Rate of amputation</b> </p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.32</b> (0.09 to 1.15) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>95</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<sup>1,2</sup><br/><b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>182 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>58 per 1000</b> </p> <p>(16 to 209)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> one single study (doubt about reproducibility of data), downgraded by one level<br/><sup>2</sup> conflict of interest not stated but it was not considered sufficient to downgrade the certainty of evidence </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">(Oral or intravenous) prostanoid versus aspirin treatment for Buerger's disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/full#CD011033-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011033-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Intravenous prostacyclin analogue versus intravenous prostaglandin analogue for treatment of Buerger's disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Intravenous prostacyclin analogue versus intravenous prostaglandin analogue for treatment of Buerger's disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with Buerger's disease </p> <p><b>Settings:</b> hospital and community </p> <p><b>Intervention:</b> intravenous prostacyclin analogue (clinprost, iloprost) </p> <p><b>Comparison:</b> intravenous prostaglandin analogue (alprostadil) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects * (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with intravenous prostaglandin analogue (alprostadil)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with intravenous prostacyclin analogue (clinprost, iloprost)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Ulcer healing</b> </p> <p>Follow‐up: 28 days</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.13</b> (0.76 to 1.69) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>89<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<sup>1,2,3,4</sup><br/><b>very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>480 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>542 per 1000</b> </p> <p>(365 to 811)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>486 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>550 per 1000</b><br/>(370 to 822) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Complete relief of pain</b> </p> <p>Follow‐up: 28 days</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.57</b> (0.72 to 3.44) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>38</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<sup>2,3,5</sup><br/><b>low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>318 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>500 per 1000</b> </p> <p>(229 to 1000)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Rate of amputation</b> </p> <p>Follow‐up: 28 days</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate of amputation was not appraised by the studies in this comparison</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> adoption of 'as‐treated' (per‐protocol) analyses, downgraded by one level<br/><sup>2</sup> absence of patients' smoking history, downgraded by one level<br/><sup>3</sup> conflict of interest not stated but it was not considered sufficient to downgrade the certainty of evidence<br/><sup>4</sup> small number of participants, downgraded by one level<br/><sup>5</sup> one single study (doubt about reproducibility of data), downgraded by one level </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Intravenous prostacyclin analogue versus intravenous prostaglandin analogue for treatment of Buerger's disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/full#CD011033-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011033-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">(Oral or intravenous) prostanoid versus placebo for treatment of Buerger's disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Oral prostacyclin analogue (iloprost) versus placebo for treatment of Buerger's disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with Buerger's disease </p> <p><b>Settings:</b> hospital and community </p> <p><b>Intervention:</b> oral prostacyclin analogue (iloprost) in two doses: 200 mcg and 400 mcg </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects * (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with oral prostacyclin analogue (iloprost)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Ulcer healing</b> </p> <p>Follow‐up: 8 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population (200 mcg)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.11</b> (0.54 to 2.29) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>133</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<sup>1,2</sup><br/><b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>171 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>190 per 1000</b> </p> <p>(93 to 393)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population (400 mcg)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.90</b> (0.42 to 1.93) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>135</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<sup>1,2</sup><br/><b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>171 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>154 per 1000</b> </p> <p>(72 to 331)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Complete relief of rest pain</b> </p> <p>Follow‐up: 8 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population (200 mcg)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.14</b> (0.79 to 1.63) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>207</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<sup>1,2</sup><br/><b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>343 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>391 per 1000</b> </p> <p>(271 to 559)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population (400 mcg)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.11</b> (0.77 to 1.59) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>210</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<sup>1,2</sup><br/><b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>343 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>381 per 1000</b> </p> <p>(264 to 546)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Rate of amputation</b> </p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population (200 mcg)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.54</b> (0.19 to 1.56) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>209</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<sup>1,2</sup><br/><b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>87 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>47 per 1000</b> </p> <p>(17 to 136)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population (400 mcg)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.42</b> (0.13 to 1.31) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>213</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<sup>1,2</sup><br/><b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>87 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>37 per 1000</b> </p> <p>(11 to 114)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> one single study (doubt about reproducibility of data), downgraded by one level<br/><sup>2</sup> conflict of interest not stated but it was not considered sufficient to downgrade the certainty of evidence </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">(Oral or intravenous) prostanoid versus placebo for treatment of Buerger's disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/full#CD011033-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011033-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Any pharmacological agent versus placebo or any other pharmacological agent for treatment of Buerger's disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Folic acid versus placebo for treatment of Buerger's disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with Buerger's disease<br/><b>Settings:</b> community<br/><b>Intervention:</b> folic acid </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects * (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="table-header separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p>Risk with p<b>lacebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p>Risk with f<b>olic acid</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ulcer healing</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ulcer healing was not appraised by the study in this comparison</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Pain</b> <br/>VAS. Scale from: 0 to 10; higher score = more pain </p> <p>Follow‐up: 0, 2, 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Baseline</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>30<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<sup>1</sup><br/><b>very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pain in the placebo group was<br/><b>5.09 points</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pain in the intervention group was<br/><b>1.17 higher</b><br/>(0.66 lower to 3.00 higher) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>2 months</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>30<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<sup>1</sup><br/><b>very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pain in the placebo group was<br/><b>5.75 points</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pain in the intervention group was<br/><b>0.3 lower</b><br/>(2.04 lower to 1.44 higher) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>6 months</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>30<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<sup>1</sup><br/><b>very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pain in the placebo group was<br/><b>4.82 points</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pain in the intervention group was<br/><b>1.36 lower</b><br/>(3.17 lower to 0.45 higher) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Change in rate of amputation</b> </p> <p>(Difference in number of amputations at start of treatment)</p> <p>Follow‐up: 2 and 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>2 months</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>30<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<sup>1</sup><br/><b>very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No new cases of amputations two months after start of treatment</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>see comment</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>6 months</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>30<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<sup>1</sup><br/><b>very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No new cases of amputations six months after start of treatment</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>see comment</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>MD</b> : mean difference; <b>VAS</b>: visual analogue scale </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> participants without critical ischaemia, resulting in absence of amputations and no differences in pain score in both groups, one single small study ‐ downgraded by three levels </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Any pharmacological agent versus placebo or any other pharmacological agent for treatment of Buerger's disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/full#CD011033-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011033-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Intravenous prostacyclin analogue (iloprost) versus oral aspirin</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Ulcer healing (4 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Complete relief of rest pain (4 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Rate of amputation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Intravenous prostacyclin analogue (iloprost) versus oral aspirin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/references#CD011033-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011033-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Prostacyclin versus prostaglandin E1</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Ulcer healing <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.76, 1.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Complete relief of pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Prostacyclin versus prostaglandin E1</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/references#CD011033-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011033-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Oral prostacyclin analogue (iloprost) versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Ulcer healing (8 weeks) ‐ iloprost 200 mcg <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Ulcer healing (8 weeks) ‐ iloprost 400 mcg <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Ulcer healing (6 months) ‐ iloprost 200 mcg <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Ulcer healing (6 months) ‐ iloprost 400 mcg <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.5 Complete relief of rest pain (8 weeks) ‐ iloprost 200 mcg <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.6 Complete relief of rest pain (8 weeks) ‐ iloprost 400 mcg <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.7 Complete relief of rest pain (6 months) ‐ iloprost 200 mcg <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.8 Complete relief of rest pain (6 months) ‐ iloprost 400 mcg <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.9 Rate of amputation ‐ iloprost 200 mcg <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.10 Rate of amputation ‐ iloprost 400 mcg <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Oral prostacyclin analogue (iloprost) versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/references#CD011033-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011033-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Folic acid versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Pain (0 month) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Pain (2 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 Pain (6 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.4 Change in rate of amputation (2 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.5 Change in rate of amputation (6 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Folic acid versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011033.pub4/references#CD011033-tbl-0008">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD011033.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD011033-note-0013">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD011033-note-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD011033-note-0012">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD011033-note-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD011033-note-0011">Polski</a> </li> <li class="section-language"> <a class="" href="ru#CD011033-note-0008">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD011033-note-0006">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD011033-note-0007">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011033\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011033\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011033\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011033\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011033\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011033\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011033\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011033\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011033\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011033\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011033\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011033\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011033\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011033\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011033\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011033\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011033\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011033\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=7a2tKMcJ&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011033.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011033.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD011033.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD011033.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011033.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740715694189"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011033.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740715694192"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011033.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d8d55dba99371',t:'MTc0MDcxNTY5NC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 